Amedeo Smart

Free Medical Literature Service

 

Amedeo

Liver Cirrhosis
  Free Subscription

Articles published in
J Hepatol
    May 2024
  1. ANDREWS TS, Nakib D, Perciani CT, Ma XZ, et al
    Single-cell, single-nucleus, and spatial transcriptomics characterization of the immunological landscape in the healthy and PSC human liver.
    J Hepatol. 2024;80:730-743.
    >> Share

  2. XIAO H, Niu D, Zhang B
    Combined inhibition of Stat3 and periostin synergistically protects mice against liver fibrosis.
    J Hepatol. 2024;80:e207-e209.
    >> Share

    April 2024
  3. KONDILI LA, Lazarus JV, Jepsen P, Murray F, et al
    Inequities in primary liver cancer in Europe: The state of play.
    J Hepatol. 2024;80:645-660.
    >> Share

    March 2024
  4. D'AMICO G, Perricone G
    Unaswered questions for non-acute (NAD) and acute (AD) decompensation in cirrhosis.
    J Hepatol. 2024 Mar 26:S0168-8278(24)00210-1. doi: 10.1016/j.jhep.2024.
    >> Share

  5. NADIM MK, Kellum JA, Forni L, Francoz C, et al
    Acute kidney injury in patients with Cirrhosis: Acute disease quality Initiative (ADQI) and international Club of ascites (ICA) joint multidisciplinary consensus meeting.
    J Hepatol. 2024 Mar 23:S0168-8278(24)00214-9. doi: 10.1016/j.jhep.2024.
    >> Share

  6. MA AT, Sole C, Juanola A, Escude L, et al
    Prospective validation of the EASL management algorithm for acute kidney injury in cirrhosis.
    J Hepatol. 2024 Mar 11:S0168-8278(24)00157-0. doi: 10.1016/j.jhep.2024.
    >> Share

  7. GE X, Desert R, Magdaleno F, Han H, et al
    Redox-sensitive high-mobility group box-1 isoforms contribute to liver fibrosis progression and resolution in mice.
    J Hepatol. 2024;80:482-494.
    >> Share

  8. BENDIXEN SM, Jakobsgaard PR, Hansen D, Hejn KH, et al
    Single cell-resolved study of advanced murine MASH reveals a homeostatic pericyte signaling module.
    J Hepatol. 2024;80:467-481.
    >> Share

  9. LARRUE H, Bureau C, D'Amico G
    Reply to: "Comment on 'TIPS prevents further decompensation and improves survival in patients with cirrhosis and portal hypertension in an individual patient data meta-analysis'": Further decompensation should now be used as a clinically relevant outc
    J Hepatol. 2024;80:e109-e110.
    >> Share

    February 2024
  10. ARTRU F, Reiberger T
    One - or more - blind spot(s) unveiled in the new definition of decompensated cirrhosis.
    J Hepatol. 2024 Feb 8:S0168-8278(24)00118-1. doi: 10.1016/j.jhep.2024.
    >> Share

  11. HUANG CH, Tsai MH, Lin CY
    Identifying the pivotal role of non-acute decompensation as a precursor to acute decompensation in cirrhosis.
    J Hepatol. 2024 Feb 7:S0168-8278(24)00119-3. doi: 10.1016/j.jhep.2024.
    >> Share

  12. SILVA H, King JJ, Thorburn D, Luong TV, et al
    A rare cause of liver fibrosis in an adult patient.
    J Hepatol. 2024;80:e48-e50.
    >> Share

  13. LUO N, Zhang X, Huang J, Chen H, et al
    Prevalence of steatotic liver disease and associated fibrosis in the United States: Results from NHANES 2017-March 2020.
    J Hepatol. 2024;80:e70-e71.
    >> Share

    January 2024
  14. NING Z
    An in-depth exploration of new clinical and prognostic characteristics of decompensated liver cirrhosis patterns.
    J Hepatol. 2024 Jan 31:S0168-8278(24)00104-1. doi: 10.1016/j.jhep.2024.
    >> Share

  15. CAMPION D, Caviglia GP, Alessandria C
    Reply to "The impact of infections on the onset of contrast-associated acute kidney injury in patients with cirrhosis".
    J Hepatol. 2024 Jan 31:S0168-8278(24)00102-8. doi: 10.1016/j.jhep.2024.
    >> Share

  16. NAKANO M, Kawaguchi M, Kawaguchi T
    Almost Identical Values of Various Noninvasive Indexes for Hepatic Fibrosis and Steatosis between NAFLD and MASLD in Asia.
    J Hepatol. 2024 Jan 13:S0168-8278(24)00037-0. doi: 10.1016/j.jhep.2023.
    >> Share

  17. JACHS M, Hartl L, Simbrunner B, Semmler G, et al
    Prognostic performance of non-invasive tests for portal hypertension is comparable to that of hepatic venous pressure gradient.
    J Hepatol. 2024 Jan 11:S0168-8278(24)00009-6. doi: 10.1016/j.jhep.2023.
    >> Share

  18. TERGAST TL, Maasoumy B
    The impact of infections on the onset of contrast-associated acute kidney injury in patients with cirrhosis.
    J Hepatol. 2024 Jan 3:S0168-8278(24)00001-1. doi: 10.1016/j.jhep.2023.
    >> Share

  19. BALCAR L, Mandorfer M, Hernandez-Gea V, Procopet B, et al
    Predicting survival in patients with 'non-high-risk' acute variceal bleeding receiving beta-blockers+ligation to prevent re-bleeding.
    J Hepatol. 2024;80:73-81.
    >> Share

    December 2023
  20. TONON M, D'Ambrosio R, Calvino V, Tosetti G, et al
    A new clinical and prognostic characterization of the patterns of decompensation of cirrhosis.
    J Hepatol. 2023 Dec 16:S0168-8278(23)05359-X. doi: 10.1016/j.jhep.2023.
    >> Share

  21. VUKOTIC R, Di Donato R, Bosch J, Andreone P, et al
    Reply letter to the letter to the editor entitled: "5-mthf enhances the portal pressure reduction achieved with propranolol in patients with cirrhosis: a randomized placebo-controlled trial: was an accurate statistical analysis performed?".
    J Hepatol. 2023 Dec 12:S0168-8278(23)05302-3. doi: 10.1016/j.jhep.2023.
    >> Share

  22. NARDELLI S, Riggio O, Marra F, Gioia S, et al
    Episodic overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt does not increase mortality in patients with cirrhosis.
    J Hepatol. 2023 Dec 12:S0168-8278(23)05310-2. doi: 10.1016/j.jhep.2023.
    >> Share

  23. RATZIU V, Harrison SA, Hajji Y, Magnanensi J, et al
    NIS2+(TM) as a screening tool to optimize patient selection in metabolic dysfunction-associated steatohepatitis clinical trials.
    J Hepatol. 2023 Dec 5:S0168-8278(23)05270-4. doi: 10.1016/j.jhep.2023.
    >> Share

  24. ZANETTO A, Senzolo M, Pelizzaro F, Mescoli C, et al
    A rare cause of painful hepatomegaly.
    J Hepatol. 2023;79:e228-e230.
    >> Share

  25. SIMON TG, Roelstraete B, Hagstrom H, Loomba R, et al
    Progression of non-alcoholic fatty liver disease and long-term outcomes: A nationwide paired liver biopsy cohort study.
    J Hepatol. 2023;79:1366-1373.
    >> Share

    October 2023
  26. BALLESTER MP, Tranah TH, Balcar L, Fiorillo A, et al
    Corrigendum to "Development and validation of the AMMON-OHE model to predict risk of overt hepatic encephalopathy occurrence in outpatients with cirrhosis" [J Hepatol 79(4) (2023 Oct) 967-976].
    J Hepatol. 2023 Oct 31:S0168-8278(23)05179-6. doi: 10.1016/j.jhep.2023.
    >> Share

  27. FERNANDEZ-GARZA LE
    5-MTHF enhances the portal pressure reduction achieved with propranolol in patients with cirrhosis: A randomized placebo-controlled trial. Was an accurate statistical analysis performed?
    J Hepatol. 2023 Oct 25:S0168-8278(23)05228-5. doi: 10.1016/j.jhep.2023.
    >> Share

  28. CAMPION D, Ponzo P, Risso A, Caropreso P, et al
    A prospective, multicenter, three-cohort study evaluating contrast-induced acute kidney injury (CI-AKI) in patients with cirrhosis.
    J Hepatol. 2023 Oct 19:S0168-8278(23)05176-0. doi: 10.1016/j.jhep.2023.
    >> Share

  29. MURRAY SM, Pose E, Wittner M, Londono MC, et al
    Immune responses and clinical outcomes after COVID-19 vaccination in patients with liver disease and in liver transplant recipients.
    J Hepatol. 2023 Oct 18:S0168-8278(23)05174-7. doi: 10.1016/j.jhep.2023.
    >> Share

  30. MAIWALL R, Rao Pasupuleti SS, Sarin SK
    AUTHORS REPLY: High versus low target mean arterial pressure in septic shock in cirrhosis-A personalized TARGET-C approach may solve the conundrum!
    J Hepatol. 2023 Oct 13:S0168-8278(23)05144-9. doi: 10.1016/j.jhep.2023.
    >> Share

  31. CHEN X, Pan J, Zhu Y
    Anticoagulation for cirrhosis with portal vein thrombosis: Still a road to be explored.
    J Hepatol. 2023 Oct 11:S0168-8278(23)05163-2. doi: 10.1016/j.jhep.2023.
    >> Share

  32. CHE-TO LAI J, Lai-Hung Wong G, Cheuk-Fung Yip T
    Reply to "For long-term outcomes, is the impact of cirrhosis more important than HBsAg seroclearance?".
    J Hepatol. 2023 Oct 9:S0168-8278(23)05165-6. doi: 10.1016/j.jhep.2023.
    >> Share

  33. ABERG F, Savikko J, Eerola V, Nordin A, et al
    High prevalence of liver fibrosis and cirrhosis in a nationwide sample of organ donors with liver histology.
    J Hepatol. 2023 Oct 7:S0168-8278(23)05145-0. doi: 10.1016/j.jhep.2023.
    >> Share

  34. COLAPIETRO F, Maisonneuve P, Lytvyak E, Beuers U, et al
    Incidence and predictors of hepatocellular carcinoma in patients with autoimmune hepatitis.
    J Hepatol. 2023 Oct 4:S0168-8278(23)05095-X. doi: 10.1016/j.jhep.2023.
    >> Share

    September 2023
  35. HERNAEZ R, Karvellas CJ, Liu Y, Sacleux SC, et al
    The novel SALT-M score predicts 1-year post-transplant mortality in patients with severe acute-on-chronic liver failure.
    J Hepatol. 2023;79:717-727.
    >> Share

  36. BOURSIER J, Roux M, Sanyal AJ
    Reply to: "Agile scores are a good predictor of liver-related events in patients with NAFLD".
    J Hepatol. 2023;79:e128-e129.
    >> Share

  37. HARRISON SA, Ratziu V, Magnanensi J, Hajji Y, et al
    NIS2+, an optimisation of the blood-based biomarker NIS4(R) technology for the detection of at-risk NASH: A prospective derivation and validation study.
    J Hepatol. 2023;79:758-767.
    >> Share

  38. WONG VW, Ekstedt M, Wong GL, Hagstrom H, et al
    Changing epidemiology, global trends and implications for outcomes of NAFLD.
    J Hepatol. 2023;79:842-852.
    >> Share

  39. LIANG JX, Ampuero J, Niu H, Imajo K, et al
    An individual patient data meta-analysis to determine cut-offs for and confounders of NAFLD-fibrosis staging with magnetic resonance elastography.
    J Hepatol. 2023;79:592-604.
    >> Share

  40. SHARMA N, Pandey S, Yadav M, Mathew B, et al
    Biomolecular map of albumin identifies signatures of severity and early mortality in acute liver failure.
    J Hepatol. 2023;79:677-691.
    >> Share

  41. PERON JM, Larrue H, Izopet J, Buti M, et al
    The pressing need for a global HEV vaccine.
    J Hepatol. 2023;79:876-880.
    >> Share

  42. NAKATSUKA T, Tateishi R, Sato M, Fujishiro M, et al
    Agile scores are a good predictor of liver-related events in patients with NAFLD.
    J Hepatol. 2023;79:e126-e127.
    >> Share

    August 2023
  43. EBRAHIMI F, Hagstrom H, Sun J, Bergman D, et al
    Familial Coaggregation of MASLD with Hepatocellular Carcinoma and Adverse Liver Outcomes: Nationwide Multigeneration Cohort Study.
    J Hepatol. 2023 Aug 28:S0168-8278(23)05071-7. doi: 10.1016/j.jhep.2023.
    >> Share

  44. BALLESTER MP, Carbonell-Asins JA, Balcar L, Reiberger T, et al
    Reply to: Ammonia predicts clinical outcomes in cirrhosis - but there are caveats to consider.
    J Hepatol. 2023 Aug 23:S0168-8278(23)05068-7. doi: 10.1016/j.jhep.2023.
    >> Share


  45. EASL Clinical Practice Guidelines on acute-on-chronic liver failure.
    J Hepatol. 2023;79:461-491.
    >> Share

  46. TSOCHATZIS EA
    Screening for liver fibrosis - sequential non-invasive testing works best.
    J Hepatol. 2023;79:263-265.
    >> Share

  47. KOTSILITI E, Leone V, Schuehle S, Govaere O, et al
    Intestinal B cells license metabolic T-cell activation in NASH microbiota/antigen-independently and contribute to fibrosis by IgA-FcR signalling.
    J Hepatol. 2023;79:296-313.
    >> Share

  48. KJAERGAARD M, Lindvig KP, Thorhauge KH, Andersen P, et al
    Using the ELF test, FIB-4 and NAFLD fibrosis score to screen the population for liver disease.
    J Hepatol. 2023;79:277-286.
    >> Share

  49. TACKE F, Puengel T, Loomba R, Friedman SL, et al
    An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH.
    J Hepatol. 2023;79:552-566.
    >> Share

  50. DEVARBHAVI H, Asrani SK, Arab JP, Nartey YA, et al
    Global burden of liver disease: 2023 update.
    J Hepatol. 2023;79:516-537.
    >> Share

    July 2023
  51. PATIDAR KR, Belcher JM, Regner KR, St Hillien SA, et al
    Incidence and outcomes of acute kidney injury including hepatorenal syndrome in hospitalized patients with cirrhosis in the US.
    J Hepatol. 2023 Jul 28:S0168-8278(23)04990-5. doi: 10.1016/j.jhep.2023.
    >> Share

  52. SANYAL AJ, Ratziu V, Loomba R, Anstee QM, et al
    Results from a new efficacy and safety analysis of the REGENERATE trial of obeticholic acid for treatment of pre-cirrhotic fibrosis due to nonalcoholic steatohepatitis.
    J Hepatol. 2023 Jul 28:S0168-8278(23)04993-0. doi: 10.1016/j.jhep.2023.
    >> Share

  53. TAPPER EB, Bajaj JS
    Ammonia predicts clinical outcomes in cirrhosis - but there are caveats to consider.
    J Hepatol. 2023 Jul 27:S0168-8278(23)05003-1. doi: 10.1016/j.jhep.2023.
    >> Share

  54. VUKOTIC R, Di Donato R, Roncarati G, Simoni P, et al
    5-MTHF enhances the portal pressure reduction achieved with propranolol in patients with cirrhosis: A randomized placebo-controlled trial.
    J Hepatol. 2023 Jul 21:S0168-8278(23)04940-1. doi: 10.1016/j.jhep.2023.
    >> Share

  55. AGARWAL B, Canizares RB, Saliba F, Ballester MP, et al
    Randomized, controlled clinical trial of the DIALIVE liver dialysis device versus standard of care in patients with acute-on- chronic liver failure.
    J Hepatol. 2023;79:79-92.
    >> Share

  56. HACKSTEIN CP, Spitzer J, Symeonidis K, Horvatic H, et al
    Interferon-induced IL-10 drives systemic T-cell dysfunction during chronic liver injury.
    J Hepatol. 2023;79:150-166.
    >> Share

  57. VILLANUEVA C, Torres F, Tripathi D, Bosch J, et al
    Reply to: "Carvedilol in patients with compensated cirrhosis: The ongoing benefits of definitive randomised trials over meta-analysis in patients with small varices".
    J Hepatol. 2023;79:e23-e24.
    >> Share

  58. SCHEINER B, Balcar L, Lisman T, Mandorfer M, et al
    Reply to: 'From coagulation imbalance to prediction of advanced chronic liver disease decompensation: The wind of change?'.
    J Hepatol. 2023;79:e27-e28.
    >> Share

  59. PONZIANI FR, Santopaolo F, Gasbarrini A, De Cristofaro R, et al
    From coagulation imbalance to prediction of advanced chronic liver disease decompensation: The wind of change?
    J Hepatol. 2023;79:e25-e27.
    >> Share

  60. RIDOLA L, Riggio O
    Comment to: "TIPS prevents further decompensation and improves survival in patients with cirrhosis and portal hypertension in an individual patient data meta-analysis.".
    J Hepatol. 2023 Jul 1:S0168-8278(23)04938-3. doi: 10.1016/j.jhep.2023.
    >> Share

  61. LI Z, Hu Y, Zou B
    The vaccine-response in patients with cirrhosis after COVID-19 vaccination: A systematic analysis of 168,245 cirrhotic patients.
    J Hepatol. 2023 Jul 1:S0168-8278(23)04935-8. doi: 10.1016/j.jhep.2023.
    >> Share

    June 2023
  62. AGRAWAL D, Ariga KK
    Target mean arterial pressure in critically ill cirrhotic patients with septic shock: More is not always better!
    J Hepatol. 2023 Jun 29:S0168-8278(23)04931-0. doi: 10.1016/j.jhep.2023.
    >> Share

  63. CASSANO SANTOS U, Coelho de Souza MDG, Ferreira da Motta Rezende G
    Selection of patients with portal hypertension and cirrhosis with real benefit of beta-blockers: still a current challenge.
    J Hepatol. 2023 Jun 26:S0168-8278(23)00428-2. doi: 10.1016/j.jhep.2023.
    >> Share

  64. NAYAGAM JS, Masson S, Ferguson JW, Griffiths W, et al
    Where does genetic testing fit in the diagnostic pathway of patients with cryptogenic cirrhosis?
    J Hepatol. 2023 Jun 26:S0168-8278(23)00429-4. doi: 10.1016/j.jhep.2023.
    >> Share

  65. TAVABIE O
    Defining characteristics and outcomes for patients with non-alcoholic fatty liver disease admitted to hospital with decompensated cirrhosis.
    J Hepatol. 2023 Jun 12:S0168-8278(23)00413-0. doi: 10.1016/j.jhep.2023.
    >> Share

  66. LIM WH, Ng CH, Hao Tan DJ, Tseng M, et al
    Natural history of NASH cirrhosis in liver transplant waitlist registrants.
    J Hepatol. 2023 Jun 10:S0168-8278(23)00412-9. doi: 10.1016/j.jhep.2023.
    >> Share

  67. ELKRIEF L, Ganne-Carrie N, Manceau H, Tanguy M, et al
    Hepatocyte-derived biomarkers predict liver-related events at 2 years in Child-Pugh class A alcohol-related cirrhosis.
    J Hepatol. 2023 Jun 9:S0168-8278(23)00401-4. doi: 10.1016/j.jhep.2023.
    >> Share

  68. LIU X, Wen X, Lu F
    Letter to the editor: For long-term outcomes, is the impact of cirrhosis more important than HBsAg seroclearance?
    J Hepatol. 2023 Jun 9:S0168-8278(23)00402-6. doi: 10.1016/j.jhep.2023.
    >> Share

  69. SENZOLO M, Garcia-Pagan JC
    A major research gap: the use of anticoagulants in cirrhosis.
    J Hepatol. 2023 Jun 9:S0168-8278(23)00407-5. doi: 10.1016/j.jhep.2023.
    >> Share

  70. FAN R, Chen L, Zhao S, Yang H, et al
    Novel, high accuracy models for hepatocellular carcinoma prediction based on longitudinal data and cell-free DNA signatures.
    J Hepatol. 2023 Jun 9:S0168-8278(23)00416-6. doi: 10.1016/j.jhep.2023.
    >> Share

  71. ALBILLOS A, Guerrero A, Tellez L
    Reply to: "Anticoagulation to prevent disease progression in patients with cirrhosis".
    J Hepatol. 2023 Jun 8:S0168-8278(23)00414-2. doi: 10.1016/j.jhep.2023.
    >> Share

  72. BALLESTER MP, Tranah TH, Balcar L, Fiorillo A, et al
    Development and validation of the AMMON-OHE model to predict risk of overt hepatic encephalopathy occurrence in outpatients with cirrhosis.
    J Hepatol. 2023 Jun 3:S0168-8278(23)00351-3. doi: 10.1016/j.jhep.2023.
    >> Share

  73. ARTRU F, Goldberg D, Kamath PS
    Should patients with acute-on-chronic liver failure grade 3 receive higher priority for liver transplantation?
    J Hepatol. 2023;78:1118-1123.
    >> Share

  74. TANDON P, Zanetto A, Piano S, Heimbach JK, et al
    Liver transplantation in the patient with physical frailty.
    J Hepatol. 2023;78:1105-1117.
    >> Share

    May 2023
  75. INNES H, Nahon P
    Statistical perspectives on using hepatocellular carcinoma risk models to inform surveillance decisions.
    J Hepatol. 2023 May 18:S0168-8278(23)00334-3. doi: 10.1016/j.jhep.2023.
    >> Share

  76. SHAWCROSS DL, Thabut D, Amodio P
    Ammonia - an enduring foe - What evaluating whole body ammonia metabolism can teach us about cirrhosis and therapies treating hepatic encephalopathy.
    J Hepatol. 2023 May 11:S0168-8278(23)00327-6. doi: 10.1016/j.jhep.2023.
    >> Share

  77. LARRUE H, D'Amico G, Olivas P, Lv Y, et al
    TIPS prevents further decompensation and improves survival in patients with cirrhosis and portal hypertension in an individual patient data meta-analysis.
    J Hepatol. 2023 May 2:S0168-8278(23)00314-8. doi: 10.1016/j.jhep.2023.
    >> Share

  78. DI MARTINO V
    Methotrexate-induced liver fibrosis: The end of a long-held belief.
    J Hepatol. 2023;78:896-897.
    >> Share

  79. ATALLAH E, Grove JI, Crooks C, Burden-Teh E, et al
    Risk of liver fibrosis associated with long-term methotrexate therapy may be overestimated.
    J Hepatol. 2023;78:989-997.
    >> Share

    April 2023
  80. MAIWALL R, Rao Pasupuleti SS, Hidam AK, Kumar A, et al
    A randomized-controlled trial (TARGET-C) of high vs. low target mean arterial pressure in patients with cirrhosis and septic shock.
    J Hepatol. 2023 Apr 21:S0168-8278(23)00229-5. doi: 10.1016/j.jhep.2023.
    >> Share

  81. ERIKSEN PL, Djernes L, Vilstrup H, Ott P, et al
    Clearance and production of ammonia quantified in humans by constant ammonia infusion - the effects of cirrhosis and ammonia targeting treatments.
    J Hepatol. 2023 Apr 13:S0168-8278(23)00220-9. doi: 10.1016/j.jhep.2023.
    >> Share

  82. JIN K, Shi Y, Zhang H, Zhangyuan G, et al
    A TNFalpha/Miz1-positive feedback loop inhibits mitophagy in hepatocytes and propagates nonalcoholic steatohepatitis.
    J Hepatol. 2023 Apr 9:S0168-8278(23)00215-5. doi: 10.1016/j.jhep.2023.
    >> Share

  83. VERMA N, Garg P, Bhardwaj A, Sarohi V, et al
    Candida leucine aminopeptidase: a novel mycoprotein linked to invasive candidiasis and mortality in acutely decompensated cirrhosis.
    J Hepatol. 2023 Apr 8:S0168-8278(23)00216-7. doi: 10.1016/j.jhep.2023.
    >> Share

    March 2023
  84. TOSETTI G, Degasperi E, Farina E, Primignani M, et al
    Carvedilol to reduce the risk of decompensation in patients with compensated cirrhosis: really needed also in patients with HCV cured or HBV suppressed viral cirrhosis?
    J Hepatol. 2023 Mar 30:S0168-8278(23)00203-9. doi: 10.1016/j.jhep.2023.
    >> Share

  85. LISMAN T, Bernal W, Luyendyk JP
    Anticoagulation to prevent disease progression in patients with cirrhosis.
    J Hepatol. 2023 Mar 28:S0168-8278(23)00198-8. doi: 10.1016/j.jhep.2023.
    >> Share

  86. BAWEJA S, Kumari A, Negi P, Tomar A, et al
    Hepatopulmonay syndrome is associated with low sphingosine-1-phosphate levels and can be ameliorated by the functional agonist fingolimod.
    J Hepatol. 2023 Mar 28:S0168-8278(23)00192-7. doi: 10.1016/j.jhep.2023.
    >> Share

  87. MANGINI C, Gagliardi R, Causin F, Angeli P, et al
    Letter to the Editor: An isolated insular stroke mimics a bout of overt hepatic encephalopathy in a patient with cirrhosis.
    J Hepatol. 2023 Mar 19:S0168-8278(23)00179-4. doi: 10.1016/j.jhep.2023.
    >> Share

  88. VIOLI F, Pignatelli P, Cammisotto V
    Platelet defetcts in cirrhosis: fact or fiction?
    J Hepatol. 2023 Mar 8:S0168-8278(23)00173-3. doi: 10.1016/j.jhep.2023.
    >> Share

  89. BANTEL H, Schulze-Osthoff K
    Non-invasive tests for evaluating treatment response in NAFLD.
    J Hepatol. 2023;78:e101-e102.
    >> Share

  90. DURAND F, Kellum JA, Nadim MK
    Fluid Resuscitation in Patients with Cirrhosis and Sepsis: A Multidisciplinary Perspective.
    J Hepatol. 2023 Mar 1:S0168-8278(23)00113-7. doi: 10.1016/j.jhep.2023.
    >> Share

    February 2023
  91. GUERRERO A, Campo LD, Piscaglia F, Scheiner B, et al
    Anticoagulation improves survival in patients with cirrhosis and portal vein thrombosis: The IMPORTAL competing-risk meta-analysis.
    J Hepatol. 2023 Feb 27:S0168-8278(23)00112-5. doi: 10.1016/j.jhep.2023.
    >> Share

  92. SINGAL AG, Sanduzzi-Zamparelli M, Nahon P, Ronot M, et al
    International Liver cancer Association (ILCA) White Paper on Hepatocellular carcinoma Risk Stratification and Surveillance.
    J Hepatol. 2023 Feb 26:S0168-8278(23)00111-3. doi: 10.1016/j.jhep.2023.
    >> Share

  93. ZENG L, Li X, Peng Z
    Genetic variants improve hepatocellular carcinoma risk stratification, only in alcoholic cirrhosis patients?
    J Hepatol. 2023 Feb 22:S0168-8278(23)00102-2. doi: 10.1016/j.jhep.2023.
    >> Share

  94. EBADI M, Burra P, Zanetto A, Montano-Loza AJ, et al
    Current Treatment Strategies and Future Possibilities for Sarcopenia in Cirrhosis.
    J Hepatol. 2023 Feb 10:S0168-8278(23)00090-9. doi: 10.1016/j.jhep.2023.
    >> Share

  95. FABRELLAS N, Kunzler-Heule P, Olofson A, Jack K, et al
    Nursing Care For Patients With Cirrhosis.
    J Hepatol. 2023 Feb 6:S0168-8278(23)00082-X. doi: 10.1016/j.jhep.2023.
    >> Share

    January 2023
  96. ZANETTO A, Northup P, Roberts L, Senzolo M, et al
    Hemostasis in cirrhosis: understanding destabilising factors during acute decompensation.
    J Hepatol. 2023 Jan 25:S0168-8278(23)00022-3. doi: 10.1016/j.jhep.2023.
    >> Share

  97. TAO L, Yang G, Sun T, Tao J, et al
    Capsaicin receptor TRPV1 maintains quiescence of hepatic stellate cells in the liver via recruitment of SARM1.
    J Hepatol. 2023 Jan 17:S0168-8278(23)00013-2. doi: 10.1016/j.jhep.2022.
    >> Share

  98. ANOLLI MP, Degasperi E, Allweiss L, Sangiovanni A, et al
    A 3-Year Course Of Bulevirtide Monotherapy May Cure Hdv Infection In Cirrhotics.
    J Hepatol. 2023 Jan 3:S0168-8278(22)03475-4. doi: 10.1016/j.jhep.2022.
    >> Share

  99. MOULTON CD, Staite E, Winkley K, Heneghan MA, et al
    The association between liver fibrosis and cognitive impairment in type 2 diabetes.
    J Hepatol. 2023;78:e18-e20.
    >> Share

  100. SHEN Y, Chen H, Wu SD, Jiang W, et al
    Accuracy of transient elastography in assessing fibrosis at diagnosis in individuals with autoimmune liver disease.
    J Hepatol. 2023;78:e33-e34.
    >> Share

    December 2022
  101. MCPHAIL MJ, Patel VC, Carter B
    Carvedilol in patients with compensated cirrhosis: the ongoing benefits of definitive randomised trials over meta-analysis in patients with small varices.
    J Hepatol. 2022 Dec 31:S0168-8278(22)03471-7. doi: 10.1016/j.jhep.2022.
    >> Share

  102. ALBILLOS A, Krag A
    Beta-blockers in the era of precision medicine in patients with cirrhosis.
    J Hepatol. 2022 Dec 15:S0168-8278(22)03330-X. doi: 10.1016/j.jhep.2022.
    >> Share

  103. SANYAL AJ, Williams SA, Lavine JE, Tetri B, et al
    Defining the serum proteomic signature of hepatic steatosis, inflammation, ballooning and fibrosis in nonalcoholic fatty liver disease.
    J Hepatol. 2022 Dec 14:S0168-8278(22)03326-8. doi: 10.1016/j.jhep.2022.
    >> Share

  104. BAIGES A, Reverter JC, Garcia Pagan JC
    Reply to "Factor VIII as a potential predictor of recurrent thrombosis in patients with non-cirrhotic portal vein thrombosis".
    J Hepatol. 2022 Dec 9:S0168-8278(22)03322-0. doi: 10.1016/j.jhep.2022.
    >> Share

  105. LI Z, Hu Y, Li Q
    More efforts to explore the association between cirrhosis and COVID-19 mortality, and the association between NAFLD and severe COVID-19.
    J Hepatol. 2022 Dec 8:S0168-8278(22)03319-0. doi: 10.1016/j.jhep.2022.
    >> Share

  106. MITTEN EK, Baffy G
    Mechanotransduction in the pathogenesis of non-alcoholic fatty liver disease.
    J Hepatol. 2022;77:1642-1656.
    >> Share

  107. YIP TC, Wong VW, Lai MS, Lai JC, et al
    Risk of hepatic decompensation but not hepatocellular carcinoma decreases over time in patients with hepatitis B surface antigen loss.
    J Hepatol. 2022 Dec 1:S0168-8278(22)03314-1. doi: 10.1016/j.jhep.2022.
    >> Share

    November 2022
  108. THABUT D, Kudo M
    Treatment of portal hypertension in patients with HCC at the era of Baveno VII.
    J Hepatol. 2022 Nov 29:S0168-8278(22)03313-X. doi: 10.1016/j.jhep.2022.
    >> Share

  109. NAHON P, Bamba-Funck J, Layese R, Trepo E, et al
    Integrating genetic variants into clinical models for hepatocellular carcinoma risk stratification in cirrhosis.
    J Hepatol. 2022 Nov 22:S0168-8278(22)03294-9. doi: 10.1016/j.jhep.2022.
    >> Share

  110. LOUVET A, Bourcier V, Archambeaud I, d'Alteroche L, et al
    Low alcohol consumption influences outcomes in individuals with alcohol-related compensated cirrhosis in a French multicenter cohort.
    J Hepatol. 2022 Nov 21:S0168-8278(22)03304-9. doi: 10.1016/j.jhep.2022.
    >> Share

  111. AJMERA V, Cepin S, Tesfai K, Hofflich H, et al
    A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes.
    J Hepatol. 2022 Nov 18:S0168-8278(22)03302-5. doi: 10.1016/j.jhep.2022.
    >> Share

  112. CHOLANKERIL G, Kramer JR, Chu J, Yu X, et al
    Longitudinal changes in fibrosis markers are associated with risk of cirrhosis and hepatocellular carcinoma in non-alcoholic fatty liver disease.
    J Hepatol. 2022 Nov 16:S0168-8278(22)03299-8. doi: 10.1016/j.jhep.2022.
    >> Share

  113. LUO L, Yao X, Yang W
    Biejia-Ruangan compound and incidence of hepatocellular carcinoma.
    J Hepatol. 2022 Nov 16:S0168-8278(22)03305-0. doi: 10.1016/j.jhep.2022.
    >> Share

  114. BAJAJ JS
    Albumin for Liver-Brain Outcome Improvement Across Different Situations in Cirrhosis.
    J Hepatol. 2022 Nov 15. pii: S0168-8278(22)03298.
    >> Share

  115. SANYAL AJ, Foucquier J, Younossi ZM, Harrison SA, et al
    Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan-based Agile scores.
    J Hepatol. 2022 Nov 11. pii: S0168-8278(22)03293.
    >> Share

  116. ZHANG X, Song J, Zhang Y, Wen B, et al
    Baveno VII algorithm outperformed other models in ruling out high-risk varices in individuals with HBV-related cirrhosis.
    J Hepatol. 2022 Nov 7. pii: S0168-8278(22)03287.
    >> Share

  117. ARTZNER T, Belli LS, Faitot F, Jalan R, et al
    Attitudes toward liver transplantation for ACLF-3 patients determine equity of access.
    J Hepatol. 2022 Nov 5. pii: S0168-8278(22)03286.
    >> Share

  118. TRANAH TH, Ballester MP, Carbonell-Asins JA, Jalan R, et al
    Reply to 'Ammonia and prognosis of cirrhosis: a new perspective for identifying high risk patients'.
    J Hepatol. 2022 Nov 2. pii: S0168-8278(22)03162.
    >> Share

  119. RATZIU V, Harrison SA, Loustaud-Ratti V, Bureau C, et al
    Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH.
    J Hepatol. 2022 Nov 2. pii: S0168-8278(22)03160.
    >> Share

  120. ALLEN AM, Therneau TM, Ahmed OT, Gidener T, et al
    Clinical course of non-alcoholic fatty liver disease and the implications for clinical trial design.
    J Hepatol. 2022;77:1237-1245.
    >> Share

  121. NAOUMOV NV, Brees D, Loeffler J, Chng E, et al
    Digital pathology with artificial intelligence analyses provides greater insights into treatment-induced fibrosis regression in NASH.
    J Hepatol. 2022;77:1399-1409.
    >> Share

  122. HENDRIKX T, Porsch F, Kiss MG, Rajcic D, et al
    Soluble TREM2 levels reflect the recruitment and expansion of TREM2(+) macrophages that localize to fibrotic areas and limit NASH.
    J Hepatol. 2022;77:1373-1385.
    >> Share

  123. TRANAH TH, Ballester MP, Carbonell-Asins JA, Jalan R, et al
    Reply to 'The possible link between higher ammonia levels associated with non-alcoholic fatty liver related cirrhosis and diabetes: are we missing chronic kidney disease?'
    J Hepatol. 2022 Nov 1. pii: S0168-8278(22)03161.
    >> Share

    October 2022
  124. NOUREDDIN M, Harrison SA
    NASH Cirrhosis Trials And Major Adverse Liver Outcomes: Big Data Needed.
    J Hepatol. 2022 Oct 31. pii: S0168-8278(22)03159.
    >> Share

  125. LI B, Hong C, Fan Z, Cai S, et al
    Prognostic and therapeutic significance of microbial cell-free DNA in plasma of people with acutely decompensated cirrhosis.
    J Hepatol. 2022 Oct 26. pii: S0168-8278(22)03144.
    >> Share

  126. PRYKE R, Guha IN
    Time to focus chronic liver diseases back into the community: A review of primary care hepatology tools, pathways of care and reimbursement mechanisms.
    J Hepatol. 2022 Oct 22. pii: S0168-8278(22)03146.
    >> Share

  127. NEVENS F, Trauner M, Manns MP
    Primary biliary cholangitis as a roadmap for the development of novel treatments of cholestatic liver diseases.
    J Hepatol. 2022 Oct 19. pii: S0168-8278(22)03143.
    >> Share

  128. LI T, Lu Z
    Factor VIII as a potential predictor of recurrent thrombosis in patients with non-cirrhotic portal vein thrombosis.
    J Hepatol. 2022 Oct 11. pii: S0168-8278(22)03136.
    >> Share

  129. PERICAS JM, Tacke F, Anstee QM, Di Prospero NA, et al
    Platform trials to overcome major shortcomings of traditional clinical trials in non-alcoholic steatohepatitis? Pros and Cons.
    J Hepatol. 2022 Oct 7. pii: S0168-8278(22)03131.
    >> Share

  130. TSAI PC, Kuo HT, Hung CH, Tseng KC, et al
    Metformin reduces hepatocellular carcinoma incidence after successful antiviral therapy in patients with diabetes and chronic hepatitis C in Taiwan.
    J Hepatol. 2022 Oct 5. pii: S0168-8278(22)03129.
    >> Share

  131. LEE SK, Kwon JH, Yoon N, Lee SH, et al
    Immune-mediated liver injury represented as overlap syndrome after SARS-CoV-2 vaccination.
    J Hepatol. 2022;77:1209-1211.
    >> Share

  132. PEISELER M, Schwabe R, Hampe J, Kubes P, et al
    Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease - novel insights into cellular communication circuits.
    J Hepatol. 2022;77:1136-1160.
    >> Share

  133. DE GOTTARDI A, Sempoux C, Berzigotti A
    Porto-sinusoidal vascular disorder.
    J Hepatol. 2022;77:1124-1135.
    >> Share

  134. VAN KLEEF LA, Lu Z, Arfan Ikram M, de Groot NMS, et al
    Liver stiffness not fatty liver disease is associated with atrial fibrillation: The Rotterdam study.
    J Hepatol. 2022;77:931-938.
    >> Share

  135. BASTATI N, Beer L, Ba-Ssalamah A, Poetter-Lang S, et al
    Gadoxetic acid-enhanced MRI-derived functional liver imaging score (FLIS) and spleen diameter predict outcomes in ACLD.
    J Hepatol. 2022;77:1005-1013.
    >> Share

    September 2022
  136. ELFEKI MA, Singal AK
    The possible link between higher ammonia levels associated with non-alcoholic fatty liver related cirrhosis and diabetes: are we missing chronic kidney disease?
    J Hepatol. 2022 Sep 30. pii: S0168-8278(22)03125.
    >> Share

  137. WANG Y, Hu M, Yang H
    Cirrhosis is an independent predictor for COVID-19 mortality: A meta-analysis of confounding cofactors-controlled data.
    J Hepatol. 2022 Sep 27. pii: S0168-8278(22)03122.
    >> Share

  138. REINIS J, Petrenko O, Simbrunner B, Hofer BS, et al
    Assessment of portal hypertension severity using machine learning models in patients with compensated cirrhosis.
    J Hepatol. 2022 Sep 21. pii: S0168-8278(22)03119.
    >> Share

  139. FAGAN A, Gavis EA, Gallagher ML, Mousel T, et al
    A double-blind randomized placebo-controlled trial of albumin in patients with hepatic encephalopathy: HEAL study.
    J Hepatol. 2022 Sep 21. pii: S0168-8278(22)03116.
    >> Share

  140. RIDOLA L, Riggio O
    Ammonia and prognosis of cirrhosis: a new perspective for identifying high risk patients.
    J Hepatol. 2022 Sep 20. pii: S0168-8278(22)03112.
    >> Share

  141. ZANETTO A, Pelizzaro F, Campello E, Bulato C, et al
    Severity of systemic inflammation is the main predictor of ACLF and bleeding in patients with acutely decompensated cirrhosis.
    J Hepatol. 2022 Sep 20. pii: S0168-8278(22)03110.
    >> Share

  142. MAIWALL R, Deshmukh A, Sarin SK
    Reply to: "Response to: A randomized-controlled trial comparing 20% albumin to plasmalyte in patients with cirrhosis and sepsis-induced hypotension [ALPS trial]".
    J Hepatol. 2022 Sep 13. pii: S0168-8278(22)03069.
    >> Share

  143. PARIKH ND, Tayob N, Singal AG
    Blood-based biomarkers for hepatocellular carcinoma screening: Approaching the end of the ultrasound era?
    J Hepatol. 2022 Sep 8. pii: S0168-8278(22)03067.
    >> Share

  144. KAZANKOV K, Novelli S, Chatterjee DA, Phillips A, et al
    Evaluation of CirrhoCare(R) - A digital-health solution for home management of patients with cirrhosis.
    J Hepatol. 2022 Sep 7. pii: S0168-8278(22)03066.
    >> Share

  145. PATERNOSTRO R, Kwanten WJ, Reiberger T
    Portal hypertension is a key determinant of the risk for liver-related events in non-alcoholic fatty liver disease.
    J Hepatol. 2022 Sep 4. pii: S0168-8278(22)03062.
    >> Share

  146. GREUTER T, Yaqoob U, Gan C, Jalan-Sakrikar N, et al
    Mechanotransduction-induced glycolysis epigenetically regulates a CXCL1-dominant angiocrine signaling program in liver sinusoidal endothelial cells in vitro and in vivo.
    J Hepatol. 2022;77:723-734.
    >> Share

  147. BASELLI GA, Jamialahmadi O, Pelusi S, Ciociola E, et al
    Rare ATG7 genetic variants predispose patients to severe fatty liver disease.
    J Hepatol. 2022;77:596-606.
    >> Share

  148. BAIGES A, Procopet B, Silva-Junior G, Llop E, et al
    Incidence and factors predictive of recurrent thrombosis in patients with non-cirrhotic portal vein thrombosis.
    J Hepatol. 2022 Sep 1. pii: S0168-8278(22)03054.
    >> Share

    August 2022
  149. WHITFIELD JB, Morgan TR, Seth D
    Reply to: External validation of a genetic risk score that predicts development of alcohol-related cirrhosis.
    J Hepatol. 2022 Aug 30. pii: S0168-8278(22)03055.
    >> Share

  150. WANG Q, Zhao H, Deng Y, Zheng H, et al
    Validation of Baveno VII criteria for recompensation in entecavir-treated individuals with hepatitis B-related decompensated cirrhosis.
    J Hepatol. 2022 Aug 26. pii: S0168-8278(22)03019.
    >> Share

  151. LABENZ C, Arslanow A, Lammert F, Galle PR, et al
    Reply to: "an individualized cirrhosis screening strategy might be more cost-effective in the general population".
    J Hepatol. 2022 Aug 18. pii: S0168-8278(22)03006.
    >> Share

  152. KENNEDY L, Carpino G, Owen T, Ceci L, et al
    Secretin alleviates biliary and liver injury during late-stage primary biliary cholangitis via restoration of secretory processes.
    J Hepatol. 2022 Aug 17. pii: S0168-8278(22)02999.
    >> Share

  153. JOHN BV, Ferreira RD, Doshi A, Kaplan DE, et al
    Third dose of COVID-19 mRNA vaccine appears to overcome vaccine hyporesponsiveness in patients with cirrhosis.
    J Hepatol. 2022 Aug 16. pii: S0168-8278(22)03002.
    >> Share

  154. JI D, Chen Y, Bi J, Shang Q, et al
    Entecavir plus Biejia-Ruangan compound reduces the risk of hepatocellular carcinoma in Chinese patients with chronic hepatitis B.
    J Hepatol. 2022 Aug 16. pii: S0168-8278(22)02982.
    >> Share

  155. BOWLUS CL, Levy C, Hirschfield GM
    Reply to: "Seladelpar in patients with primary biliary cholangitis: Need for a closer look!"
    J Hepatol. 2022 Aug 14. pii: S0168-8278(22)02990.
    >> Share

  156. DEGASPERI E, Anolli MP, Uceda Renteria SC, Sambarino D, et al
    Bulevirtide monotherapy for 48 Weeks in hdv patients with compensated cirrhosis and clinically significant portal hypertension.
    J Hepatol. 2022 Aug 13. pii: S0168-8278(22)02980.
    >> Share


  157. EASL Clinical Practice Guidelines on haemochromatosis.
    J Hepatol. 2022;77:479-502.
    >> Share

  158. BUGIANESI E, Petta S
    NAFLD/NASH.
    J Hepatol. 2022;77:549-550.
    >> Share

  159. ABERG F, Luukkonen PK, But A, Salomaa V, et al
    Development and validation of a model to predict incident chronic liver disease in the general population: The CLivD score.
    J Hepatol. 2022;77:302-311.
    >> Share

    July 2022
  160. TRANAH TH, Ballester MP, Carbonell-Asins JA, Ampuero J, et al
    Plasma ammonia levels predict hospitalisation with liver-related complications and mortality in clinically stable outpatients with cirrhosis.
    J Hepatol. 2022 Jul 21. pii: S0168-8278(22)02947.
    >> Share

  161. ZHAO S, Liao X, Fan R
    An individualized cirrhosis screening strategy might be more cost-effective in the general population.
    J Hepatol. 2022 Jul 14. pii: S0168-8278(22)02937.
    >> Share

  162. MAIMONE S, Tripodi VF, Mazzeo AT
    Response to: A randomized-controlled trial comparing 20% albumin to plasmalyte in patients with cirrhosis and sepsis-induced hypotension [ALPS trial].
    J Hepatol. 2022 Jul 7. pii: S0168-8278(22)02926.
    >> Share

    June 2022
  163. CORPECHOT C, Carrat F, Gaouar F, Chau F, et al
    Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis.
    J Hepatol. 2022 Jun 28. pii: S0168-8278(22)00411.
    >> Share

  164. HUANG B, Lyu Z, Qian Q, Chen Y, et al
    NUDT1 promotes the accumulation and longevity of CD103(+) TRM cells in primary biliary cholangitis.
    J Hepatol. 2022 Jun 23. pii: S0168-8278(22)00408.
    >> Share

  165. LAMPERTICO P, Roulot D, Wedemeyer H
    BULEVIRTIDE WITH OR WITHOUT PEGIFNalpha FOR PATIENTS WITH COMPENSATED CHRONIC HEPATITIS DELTA: FROM CLINICAL TRIALS TO REAL LIFE STUDIES.
    J Hepatol. 2022 Jun 22. pii: S0168-8278(22)00373.
    >> Share

  166. JEPSEN P, Reeves H
    Signed, SEALed, detected I'm your patient with advanced fibrosis or cirrhosis!
    J Hepatol. 2022 Jun 20. pii: S0168-8278(22)00369.
    >> Share

  167. BRESCIANI N, Demagny H, Lemos V, Pontanari F, et al
    SLC25A47 is a novel determinant of hepatic mitochondrial function implicated in liver fibrosis.
    J Hepatol. 2022 Jun 14. pii: S0168-8278(22)00364.
    >> Share

  168. JOHANSEN S, Thiele M, Juel HB, Hansen T, et al
    External validation of a genetic risk score that predicts development of alcohol-related cirrhosis.
    J Hepatol. 2022 Jun 13. pii: S0168-8278(22)00365.
    >> Share

  169. CARACENI P, O'Brien A, Gines P
    Long-term albumin treatment in patients with cirrhosis and ascites.
    J Hepatol. 2022;76:1306-1317.
    >> Share

  170. LISMAN T, Caldwell SH, Intagliata NM
    Haemostatic alterations and management of haemostasis in patients with cirrhosis.
    J Hepatol. 2022;76:1291-1305.
    >> Share

  171. ANSTEE QM, Castera L, Loomba R
    Impact of non-invasive biomarkers on hepatology practice: Past, present and future.
    J Hepatol. 2022;76:1362-1378.
    >> Share

  172. RATZIU V, Francque S, Sanyal A
    Breakthroughs in therapies for NASH and remaining challenges.
    J Hepatol. 2022;76:1263-1278.
    >> Share

    May 2022
  173. VILLANUEVA C, Torres F, Sarin SK, Shah HA, et al
    Carvedilol reduces the risk of decompensation and mortality in patients with compensated cirrhosis in a competing-risk meta-analysis.
    J Hepatol. 2022 May 31. pii: S0168-8278(22)00336.
    >> Share

  174. KEMMING J, Gundlach S, Panning M, Huzly D, et al
    Mechanisms of CD8+ T cell failure in chronic hepatitis E virus infection.
    J Hepatol. 2022 May 27. pii: S0168-8278(22)00334.
    >> Share

  175. POURIKI S, Alexopoulos T, Vasilieva L, Vrioni G, et al
    Rectal colonization by resistant bacteria is associated with infection by the colonizing strain and high mortality in decompensated cirrhosis.
    J Hepatol. 2022 May 25. pii: S0168-8278(22)00328.
    >> Share

  176. MISHRA AK, Singh SP
    Seladelpar in patients with primary biliary cholangitis: Need a closer look!
    J Hepatol. 2022 May 17. pii: S0168-8278(22)00315.
    >> Share

  177. SEMMLER G, Mandorfer M
    Substantiating evidence for HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease.
    J Hepatol. 2022 May 5. pii: S0168-8278(22)00267.
    >> Share

  178. LEE BP, Cullaro G, Vosooghi A, Yao F, et al
    Discordance in categorization of acute-on-chronic liver failure in the United Network for Organ Sharing database.
    J Hepatol. 2022;76:1122-1126.
    >> Share

  179. SCHEINER B, Balcar L, Nussbaumer RJ, Weinzierl J, et al
    Factor VIII/protein C ratio independently predicts liver-related events but does not indicate a hypercoagulable state in ACLD.
    J Hepatol. 2022;76:1090-1099.
    >> Share

  180. MAHMUD N, Chapin S, Goldberg DS, Reddy KR, et al
    Statin exposure is associated with reduced development of acute-on-chronic liver failure in a Veterans Affairs cohort.
    J Hepatol. 2022;76:1100-1108.
    >> Share

  181. BOURSIER J, Hagstrom H, Ekstedt M, Moreau C, et al
    Non-invasive tests accurately stratify patients with NAFLD based on their risk of liver-related events.
    J Hepatol. 2022;76:1013-1020.
    >> Share

    April 2022
  182. TANTAI X, Yeo YH, Wang J, Ji F, et al
    Reply to: "Evaluating sarcopenia in cirrhosis patients: the role of muscle function".
    J Hepatol. 2022 Apr 30. pii: S0168-8278(22)00259.
    >> Share

  183. FERNANDEZ J, Prado V, Valdivieso M, Trebicka J, et al
    Response to: Association of rectal colonization by mdros with new infection in cirrhosis.
    J Hepatol. 2022 Apr 30. pii: S0168-8278(22)00257.
    >> Share

  184. LABENZ C, Arslanow A, Nguyen-Tat M, Nagel M, et al
    Structured Early detection of Asymptomatic Liver Cirrhosis: Results of the population-based liver screening program SEAL.
    J Hepatol. 2022 Apr 23. pii: S0168-8278(22)00244.
    >> Share

  185. MAIWALL R, Kumar A, Pasupuleti SSR, Hidam AK, et al
    A randomized-controlled trial comparing 20% albumin to plasmalyte in patients with cirrhosis and sepsis-induced hypotension [ALPS trial].
    J Hepatol. 2022 Apr 20. pii: S0168-8278(22)00239.
    >> Share

  186. YANG H, Bae SH, Nam H, Lee HL, et al
    A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance.
    J Hepatol. 2022 Apr 7. pii: S0168-8278(22)00208.
    >> Share

  187. FRASER DA, Wang X, Lund J, Nikolic N, et al
    A structurally engineered fatty acid, icosabutate, suppresses liver inflammation and fibrosis in NASH.
    J Hepatol. 2022;76:800-811.
    >> Share

  188. FROMME M, Schneider CV, Trautwein C, Brunetti-Pierri N, et al
    Alpha-1 antitrypsin deficiency: A re-surfacing adult liver disorder.
    J Hepatol. 2022;76:946-958.
    >> Share

  189. NOUREDDIN M, Truong E, Gornbein JA, Saouaf R, et al
    MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis.
    J Hepatol. 2022;76:781-787.
    >> Share

  190. SCORLETTI E, Carr RM
    A new perspective on NAFLD: Focusing on lipid droplets.
    J Hepatol. 2022;76:934-945.
    >> Share

    March 2022
  191. BOWLUS CL, Galambos MR, Aspinall RJ, Hirschfield GM, et al
    A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis.
    J Hepatol. 2022 Mar 30. pii: S0168-8278(22)00187.
    >> Share

  192. ZANETTO A, Campello E, Bulato C, Gavasso S, et al
    Increased platelet aggregation in patients with decompensated cirrhosis indicates higher risk of further decompensation and death.
    J Hepatol. 2022 Mar 29. pii: S0168-8278(22)00177.
    >> Share

  193. TAPPER EB, Essien UR, Zhao Z, Ufere NN, et al
    Racial and ethnic disparities in rifaximin use and subspecialty referrals for patients with hepatic encephalopathy in the United States.
    J Hepatol. 2022 Mar 28. pii: S0168-8278(22)00116.
    >> Share

  194. TANTAI X, Yeo YH, Wang J, Ji F, et al
    Reply to: "Gut liver muscle brain axis: a comprehensive viewpoint on prognosis in cirrhosis".
    J Hepatol. 2022 Mar 26. pii: S0168-8278(22)00182.
    >> Share

  195. XIONG J, Tian Y
    Evaluating sarcopenia in cirrhosis patients: the role of muscle function.
    J Hepatol. 2022 Mar 26. pii: S0168-8278(22)00190.
    >> Share

  196. TRIPODI A
    Cirrhosis. What are all those factor VIII and protein C for?
    J Hepatol. 2022 Mar 26. pii: S0168-8278(22)00189.
    >> Share

  197. SCHWARZ C, Chromy D, Bangert C, Schwarz M, et al
    Immediate-type hypersensitivity reaction to bulevirtide and successful desensitization in a patient with HBV/HDV-associated compensated cirrhosis.
    J Hepatol. 2022 Mar 16. pii: S0168-8278(22)00172.
    >> Share

  198. WANG Q, Zhou H, Bu Q, Wei S, et al
    Role of XBP1 in regulating the progression of non-alcoholic steatohepatitis.
    J Hepatol. 2022 Mar 12. pii: S0168-8278(22)00140.
    >> Share

  199. WHITFIELD JB, Schwantes-An TH, Darlay R, Aithal GP, et al
    Corrigendum to: 'A genetic risk score and diabetes predict development of alcohol-related cirrhosis in drinkers' [J Hepatol 2022 (76) 275-282].
    J Hepatol. 2022 Mar 11. pii: S0168-8278(22)00117.
    >> Share

  200. NAKATSUKA T, Tateishi R, Nakagomi R, Minami T, et al
    Risk stratification of hepatocellular carcinoma after hepatitis C virus eradication in patients with compensated advanced chronic liver disease in Japan.
    J Hepatol. 2022 Mar 11. pii: S0168-8278(22)00138.
    >> Share

  201. TORGERSEN J, Taddei TH, Lo Re V 3rd
    Reply to: "Is it safe to treat chronic hepatitis C patients with decompensated cirrhosis with PI-based DAA?"
    J Hepatol. 2022 Mar 10. pii: S0168-8278(22)00132.
    >> Share

  202. SINGH SP, Jindal A
    Association of rectal colonisation by MDROs with new infection in cirrhosis.
    J Hepatol. 2022 Mar 9. pii: S0168-8278(22)00135.
    >> Share

  203. INNES H, Morling JR, Buch S, Hamill V, et al
    Performance of routine risk scores for predicting cirrhosis-related morbidity in the community.
    J Hepatol. 2022 Mar 7. pii: S0168-8278(22)00129.
    >> Share


  204. EASL Clinical Practice Guidelines on prevention and management of bleeding and thrombosis in patients with cirrhosis.
    J Hepatol. 2022 Mar 2. pii: S0168-8278(21)02033.
    >> Share

  205. DEPRET F, Bouam S, Schwarzinger M, Mallet V, et al
    Reply to: "Focus on the decisions to forego life-sustaining therapies during ICU stay of patients with cirrhosis and COVID-19: A case control study from the prospective COVID-ICU database".
    J Hepatol. 2022;76:744-747.
    >> Share

  206. RINELLA ME, Dufour JF, Anstee QM, Goodman Z, et al
    Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study.
    J Hepatol. 2022;76:536-548.
    >> Share

    February 2022
  207. PATIDAR KR, Naved MA, Grama A, Adibuzzaman M, et al
    Acute Kidney Disease is Common and Associated with Poor Outcomes in Patients with Cirrhosis and Acute Kidney Injury.
    J Hepatol. 2022 Feb 22. pii: S0168-8278(22)00115.
    >> Share

  208. FONDEVILA MF, Fernandez U, Heras V, Parracho T, et al
    Inhibition of carnitine palmitoyl-transferase 1A in hepatic stellate cells protects against fibrosis.
    J Hepatol. 2022 Feb 12. pii: S0168-8278(22)00077.
    >> Share

  209. MUELLER PP, Chen Q, Ayer T, Nemutlu G, et al
    Duration and cost-effectiveness of hepatocellular carcinoma surveillance in hepatitis C patients after viral eradication.
    J Hepatol. 2022 Feb 11. pii: S0168-8278(22)00074.
    >> Share

  210. SINGAL AG, Zhang E, Narasimman M, Rich NE, et al
    HCC Surveillance Improves Early Detection, Curative Treatment Receipt, and Survival in Patients with Cirrhosis: A Systematic Review and Meta-Analysis.
    J Hepatol. 2022 Feb 6. pii: S0168-8278(22)00068.
    >> Share

  211. ENGELMANN C, Bruns T, Berg T
    Reply to: "G-CSF in acute-on-chronic liver failure - Art of 'patient selection' is paramount!"
    J Hepatol. 2022;76:473-475.
    >> Share

  212. JINDAL A, Sarin SK
    G-CSF in acute-on-chronic liver failure - Art of 'patient selection' is paramount!
    J Hepatol. 2022;76:472-473.
    >> Share

    January 2022
  213. RIDOLA L, Gioia S, Faccioli J, Riggio O, et al
    Gut liver muscle brain axis: a comprehensive viewpoint on prognosis in cirrhosis.
    J Hepatol. 2022 Jan 25. pii: S0168-8278(22)00016.
    >> Share

  214. LIMON-MIRO AT, Jackson CD, Eslamparast T, Yamanaka-Okumura H, et al
    Predicted estimates of resting energy expenditure have limited clinical utility in patients with cirrhosis.
    J Hepatol. 2022 Jan 25. pii: S0168-8278(22)00018.
    >> Share

  215. PRADO V, Hernandez-Tejero M, Mucke MM, Marco F, et al
    Rectal colonization by resistant bacteria increases the risk of infection by the colonizing strain in critically ill patients with cirrhosis.
    J Hepatol. 2022 Jan 21. pii: S0168-8278(22)00013.
    >> Share

  216. BUONOMO E, Mei S, Guinn S, Leo I, et al
    Liver Stromal Cells Restrict Macrophage Maturation and Stromal IL-6 Limits the Differentiation of Cirrhosis-linked Macrophages.
    J Hepatol. 2022 Jan 21. pii: S0168-8278(22)00007.
    >> Share

  217. WONG YJ, Nguyen MH
    Is it safe to treat chronic hepatitis C patients with decompensated cirrhosis with PI-based DAA?
    J Hepatol. 2022 Jan 21. pii: S0168-8278(22)00008.
    >> Share

  218. D'AMICO G, Bernardi M, Angeli P
    Corrigendum to 'Towards a new definition of decompensated cirrhosis' [J Hepatol 76 (2022) 202-207].
    J Hepatol. 2022 Jan 5. pii: S0168-8278(21)02300.
    >> Share

  219. LI B, He Q, Lu G, Hong C, et al
    Minor role of hemostatic alternation in portal vein thrombosis pathogenesis revealed by global measurement.
    J Hepatol. 2022;76:225-227.
    >> Share

  220. VAN KLEEF LA, Sonneveld MJ, de Man RA, de Knegt RJ, et al
    Poor performance of FIB-4 in elderly individuals at risk for chronic liver disease - implications for the clinical utility of the EASL NIT guideline.
    J Hepatol. 2022;76:245-246.
    >> Share

  221. COREY KE, Pitts R, Lai M, Loureiro J, et al
    ADAMTSL2 protein and a soluble biomarker signature identify at-risk non-alcoholic steatohepatitis and fibrosis in adults with NAFLD.
    J Hepatol. 2022;76:25-33.
    >> Share

  222. GHELFI J, Brusset B, Thony F, Decaens T, et al
    Successful management of refractory ascites in non-TIPSable patients using percutaneous thoracic duct stenting.
    J Hepatol. 2022;76:216-218.
    >> Share

    December 2021
  223. DE FRANCHIS R, Bosch J, Garcia-Tsao G, Reiberger T, et al
    Baveno VII - Renewing consensus in portal hypertension.
    J Hepatol. 2021 Dec 30. pii: S0168-8278(21)02299.
    >> Share

  224. BELLI LS, Perricone G, Jalan R
    Reply to: Sarcopenia should be evaluated in patients with acute-on-chronic liver failure and candidates to liver transplantation. Reply letter.
    J Hepatol. 2021 Dec 28. pii: S0168-8278(21)02293.
    >> Share

  225. GARRIDO A, Kim E, Teijeiro A, Sanchez PS, et al
    Histone acetylation of bile acid transporter genes plays a critical role in cirrhosis.
    J Hepatol. 2021 Dec 24. pii: S0168-8278(21)02294.
    >> Share

  226. SOUNDARARAJAN R, Gupta P
    Reply to "Abbreviated MRI to screen for HCC in patients with cirrhosis. A step forward but a long road ahead".
    J Hepatol. 2021 Dec 23. pii: S0168-8278(21)02292.
    >> Share

  227. SEMMLER G, Meyer EL, Kozbial K, Schwabl P, et al
    HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease.
    J Hepatol. 2021 Dec 3. pii: S0168-8278(21)02234.
    >> Share

  228. POHL J, Gebauer B, Gebert P, Tacke F, et al
    Predicting survival after TIPS: Child Pugh score is not inferior to MELD and FIPS score - back to basics?
    J Hepatol. 2021;75:1505-1506.
    >> Share

  229. NIELSEN MJ, Leeming DJ, Goodman Z, Friedman S, et al
    Comparison of ADAPT, FIB-4 and APRI as non-invasive predictors of liver fibrosis and NASH within the CENTAUR screening population.
    J Hepatol. 2021;75:1292-1300.
    >> Share

  230. YANG T, Poenisch M, Khanal R, Hu Q, et al
    Therapeutic HNF4A mRNA attenuates liver fibrosis in a preclinical model.
    J Hepatol. 2021;75:1420-1433.
    >> Share

    November 2021
  231. SANDUZZI-ZAMPARELLI M, Marino Z, Lens S, Sapena V, et al
    Liver cancer risk after HCV cure in patients with advanced liver disease without non-characterized nodules.
    J Hepatol. 2021 Nov 29. pii: S0168-8278(21)02228.
    >> Share

  232. SABOO K, Petrakov NV, Shamsaddini A, Fagan A, et al
    Stool microbiota are superior to saliva in distinguishing cirrhosis and hepatic encephalopathy using machine learning.
    J Hepatol. 2021 Nov 15. pii: S0168-8278(21)02183.
    >> Share

  233. D'AVOLA D, Granito A, de la Torre-Alaez M, Piscaglia F, et al
    The importance of liver functional reserve in the non-surgical treatment of Hepatocellular Carcinoma.
    J Hepatol. 2021 Nov 15. pii: S0168-8278(21)02185.
    >> Share

  234. TANTAI X, Liu Y, Yeo YH, Praktiknjo M, et al
    Effect of sarcopenia on survival in patients with cirrhosis: A systematic review and meta-analysis.
    J Hepatol. 2021 Nov 13. pii: S0168-8278(21)02174.
    >> Share

  235. PAVLIDES M, Francis S, Barnes E
    Abbreviated MRI to screen for HCC in patients with cirrhosis. A step forward but a long road ahead.
    J Hepatol. 2021 Nov 8. pii: S0168-8278(21)02169.
    >> Share

  236. PAPATHEODORIDI M, Pinzani M, Tsochatzis E
    Reply to: "Baveno VI elastography criteria for ruling in cACLD works well in patients with MAFLD" and "Transient elastography in chronic liver disease: Beware of the cut-offs!"
    J Hepatol. 2021;75:1247.
    >> Share

  237. JI Y, Li J, He Q, Zhou L, et al
    Baveno VI elastography criteria for ruling in cACLD works well in patients with MAFLD.
    J Hepatol. 2021;75:1243-1245.
    >> Share

  238. CRISTOFERI L, Nardi A, Carbone M
    Transient elastography in chronic liver disease: Beware of the cut-offs!
    J Hepatol. 2021;75:1245-1246.
    >> Share

    October 2021
  239. LOGLIO A, Ferenci P, Uceda Renteria SC, Tham CYL, et al
    Safety and effectiveness of up to 3 years' bulevirtide monotherapy in patients with HDV-related cirrhosis.
    J Hepatol. 2021 Oct 23. pii: S0168-8278(21)02119.
    >> Share

  240. WHITFIELD JB, Schwantes-An TH, Darlay R, Aithal GP, et al
    A genetic risk score and diabetes predict development of alcohol-related cirrhosis in drinkers.
    J Hepatol. 2021 Oct 13. pii: S0168-8278(21)02111.
    >> Share

  241. QING J, Ren Y, Zhang Y, Yan M, et al
    Dopamine receptor D2 antagonization normalizes profibrotic macrophage-endothelial crosstalk in non-alcoholic steatohepatitis.
    J Hepatol. 2021 Oct 11. pii: S0168-8278(21)02097.
    >> Share

  242. BAFFY G, Bosch J
    Overlooked subclinical portal hypertension in non-cirrhotic NAFLD: Is it real and how to measure it?
    J Hepatol. 2021 Oct 1. pii: S0168-8278(21)02090.
    >> Share

  243. MALLET V, Beeker N, Bouam S, Sogni P, et al
    Prognosis of French COVID-19 patients with chronic liver disease: A national retrospective cohort study for 2020.
    J Hepatol. 2021;75:848-855.
    >> Share

  244. WONG F, Piano S, Angeli P
    Reply to: Correspondence on "Clinical features and evolution of bacterial infection-related acute-on-chronic liver failure".
    J Hepatol. 2021;75:1010-1012.
    >> Share

    September 2021
  245. GIABICANI M, Le Menestrel A, Roux O, Rautou PE, et al
    Focus on the decisions to forego life-sustaining therapies during ICU stay of patients with cirrhosis and COVID-19: a case control study from the prospective COVID-ICU database.
    J Hepatol. 2021 Sep 30. pii: S0168-8278(21)02080.
    >> Share

  246. D'AMBROSIO R, Degasperi E, Anolli MP, Fanetti I, et al
    Incidence of liver and non-liver-related outcomes in patients with HCV-cirrhosis after SVR.
    J Hepatol. 2021 Sep 27. pii: S0168-8278(21)02043.
    >> Share

  247. PATEL V, Lee S, McPhail M, Da Silva K, et al
    Rifaximin reduces gut-derived inflammation and mucin degradation in cirrhosis and encephalopathy: RIFSYS randomised controlled trial.
    J Hepatol. 2021 Sep 24. pii: S0168-8278(21)02040.
    >> Share

  248. LACKNER C, Stauber RE, Tiniakos D
    Reply to: Prognostic value of histologic parameters in alcoholic hepatitis: a word of caution.
    J Hepatol. 2021 Sep 16. pii: S0168-8278(21)02035.
    >> Share

  249. ARTRU F, le Goffic C, Pageaux GP, Saliba F, et al
    Sarcopenia should be evaluated in patients with acute-on-chronic liver failure and candidates to liver transplantation.
    J Hepatol. 2021 Sep 15. pii: S0168-8278(21)02034.
    >> Share

  250. JUANOLA A, Graupera I, Elia C, Piano S, et al
    Urinary L-FABP is a promising prognostic biomarker of ACLF and mortality in patients with decompensated cirrhosis.
    J Hepatol. 2021 Sep 13. pii: S0168-8278(21)02029.
    >> Share

  251. VUPPALANCHI R, Caldwell SH, Pyrsopoulos N, deLemos AS, et al
    Proof-of-concept study to evaluate the safety and efficacy of saroglitazar in patients with primary biliary cholangitis.
    J Hepatol. 2021 Sep 3. pii: S0168-8278(21)02023.
    >> Share

  252. PAPATHEODORIDI M, Pinzani M, Tsochatzis E
    Reply to: "Do we need to re-define the Baveno VI elastography criteria for compensated advanced chronic liver disease (cACLD)?"
    J Hepatol. 2021;75:752-753.
    >> Share

  253. GENESCA J, Abraldes JG, Bosch J
    Do we need to re-define the Baveno VI elastography criteria for compensated advanced chronic liver disease (cACLD)?
    J Hepatol. 2021;75:750-752.
    >> Share

    August 2021
  254. DAI CY, Chuang WL, Yu ML
    A prospective study in predicting portal thrombosis in cirrhosis: Some Issues.
    J Hepatol. 2021 Aug 27. pii: S0168-8278(21)02010.
    >> Share

    July 2021
  255. TURON F, Driever EG, Baiges A, Cerda E, et al
    Predicting portal thrombosis in cirrhosis: A prospective study of clinical, ultrasonographic and hemostatic factors.
    J Hepatol. 2021 Jul 29. pii: S0168-8278(21)01946.
    >> Share

  256. SCHULTALBERS M, Grote-Koska D, Cornberg M, Schmidt JJ, et al
    Plasma and ascites pharmacokinetic of meropenem in patients with decompensated liver cirrhosis and spontaneous bacterial peritonitis.
    J Hepatol. 2021 Jul 23. pii: S0168-8278(21)01914.
    >> Share

  257. CLARIA J, Curto A, Moreau R, Colsch B, et al
    Untargeted lipidomics uncovers lipid signatures distinguishing severe versus moderate forms of acutely decompensated cirrhosis.
    J Hepatol. 2021 Jul 7. pii: S0168-8278(21)01895.
    >> Share

  258. BETTINGER D, Thimme R, Schultheiss M
    Reply: TIPS and liver transplantation should always be discussed together.
    J Hepatol. 2021 Jul 6. pii: S0168-8278(21)01891.
    >> Share

  259. GRANITO A, Muratori P, Muratori L
    Acute-on-chronic liver failure: a complex clinical entity in patients with autoimmune hepatitis.
    J Hepatol. 2021 Jul 3. pii: S0168-8278(21)01884.
    >> Share

  260. ALVARADO-TAPIAS E, Vilades D, Brujats A, Villanueva C, et al
    Reply letter to correspondence entitled: "Non-selective beta blockers and mortality in decompensated Cirrhosis: Is Cirrhotic Cardiomyopathy the missing link?"
    J Hepatol. 2021 Jul 2. pii: S0168-8278(21)01846.
    >> Share

  261. VAN DER MERWE S, Chokshi S, Bernsmeier C, Albillos A, et al
    The multifactorial mechanisms of bacterial infection in decompensated cirrhosis.
    J Hepatol. 2021;75 Suppl 1:S82-S100.
    >> Share

  262. TREBICKA J, Macnaughtan J, Schnabl B, Shawcross DL, et al
    The microbiota in cirrhosis and its role in hepatic decompensation.
    J Hepatol. 2021;75 Suppl 1:S67-S81.
    >> Share

  263. ENGELMANN C, Claria J, Szabo G, Bosch J, et al
    Pathophysiology of decompensated cirrhosis: Portal hypertension, circulatory dysfunction, inflammation, metabolism and mitochondrial dysfunction.
    J Hepatol. 2021;75 Suppl 1:S49-S66.
    >> Share

  264. JEPSEN P, Younossi ZM
    The global burden of cirrhosis: A review of disability-adjusted life-years lost and unmet needs.
    J Hepatol. 2021;75 Suppl 1:S3-S13.
    >> Share

  265. TANDON P, Montano-Loza AJ, Lai JC, Dasarathy S, et al
    Sarcopenia and frailty in decompensated cirrhosis.
    J Hepatol. 2021;75 Suppl 1:S147-S162.
    >> Share

  266. JALAN R, D'Amico G, Trebicka J, Moreau R, et al
    New clinical and pathophysiological perspectives defining the trajectory of cirrhosis.
    J Hepatol. 2021;75 Suppl 1:S14-S26.
    >> Share

  267. GARCIA-PAGAN JC, Francoz C, Montagnese S, Senzolo M, et al
    Management of the major complications of cirrhosis: Beyond guidelines.
    J Hepatol. 2021;75 Suppl 1:S135-S146.
    >> Share

  268. CARACENI P, Abraldes JG, Gines P, Newsome PN, et al
    The search for disease-modifying agents in decompensated cirrhosis: From drug repurposing to drug discovery.
    J Hepatol. 2021;75 Suppl 1:S118-S134.
    >> Share

  269. FERNANDEZ J, Piano S, Bartoletti M, Wey EQ, et al
    Management of bacterial and fungal infections in cirrhosis: The MDRO challenge.
    J Hepatol. 2021;75 Suppl 1:S101-S117.
    >> Share

  270. JALAN R, Szabo G
    New concepts and perspectives in decompensated cirrhosis.
    J Hepatol. 2021;75 Suppl 1:S1-S2.
    >> Share

  271. LIU Y, Xu N, Ji H
    Reply to: "Myofibroblast YAP/TAZ is dispensable for liver fibrosis in mice".
    J Hepatol. 2021;75:241-243.
    >> Share

  272. XU L, Wettschureck N, Bai Y, Yuan Z, et al
    Myofibroblast YAP/TAZ is dispensable for liver fibrosis in mice.
    J Hepatol. 2021;75:238-241.
    >> Share

  273. GUSTOT T, Stadlbauer V, Laleman W, Alessandria C, et al
    Transition to decompensation and acute-on-chronic liver failure: Role of predisposing factors and precipitating events.
    J Hepatol. 2021;75 Suppl 1:S36-S48.
    >> Share

    June 2021
  274. D'AMICO G, Bernardi M, Angeli P
    TOWARDS A NEW DEFINITION OF DECOMPENSATED CIRRHOSIS.
    J Hepatol. 2021 Jun 19. pii: S0168-8278(21)00438.
    >> Share

  275. CORPECHOT C
    Reply to: "Chronic fatigue should not be overlooked in primary biliary cholangitis".
    J Hepatol. 2021 Jun 6. pii: S0168-8278(21)00404.
    >> Share

  276. GILGENKRANTZ H, Mallat A, Moreau R, Lotersztajn S, et al
    Targeting cell-intrinsic metabolism for antifibrotic therapy.
    J Hepatol. 2021;74:1442-1454.
    >> Share

  277. BETTINGER D, Sturm L, Pfaff L, Hahn F, et al
    Refining prediction of survival after TIPS with the novel Freiburg index of post-TIPS survival.
    J Hepatol. 2021;74:1362-1372.
    >> Share

  278. ABDALLAH MA, Kuo YF, Asrani S, Wong RJ, et al
    Validating a novel score based on interaction between ACLF grade and MELD score to predict waitlist mortality.
    J Hepatol. 2021;74:1355-1361.
    >> Share

    May 2021
  279. RUDLER M, Savier E, Alioua I, Sultanik P, et al
    TIPS and liver transplantation should always be discussed together.
    J Hepatol. 2021 May 26. pii: S0168-8278(21)00347.
    >> Share

  280. CORDELL HJ, Fryett JJ, Ueno K, Darlay R, et al
    An international genome-wide meta-analysis of primary biliary cholangitis: novel risk loci and candidate drugs.
    J Hepatol. 2021 May 22. pii: S0168-8278(21)00334.
    >> Share

  281. WANG H, Wen B, Chen J
    "Small esophageal varices in compensated cirrhosis patients: to treat or not to treat?" -Reply.
    J Hepatol. 2021 May 18. pii: S0168-8278(21)00335.
    >> Share

  282. KUDO M, Matilla A, Santoro A, Melero I, et al
    CheckMate 040 Cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis.
    J Hepatol. 2021 May 12. pii: S0168-8278(21)00313.
    >> Share

  283. YEO YH, Hwang J, Jeong D, Dang N, et al
    Surveillance of patients with cirrhosis remains suboptimal in the United States.
    J Hepatol. 2021 May 6. pii: S0168-8278(21)00307.
    >> Share

  284. PAPATHEODORIDI M, Hiriart JB, Lupsor-Platon M, Bronte F, et al
    Refining the Baveno VI elastography criteria for the definition of compensated advanced chronic liver disease.
    J Hepatol. 2021;74:1109-1116.
    >> Share

  285. ZACCHERINI G, Aguilar F, Caraceni P, Claria J, et al
    Assessing the role of amino acids in systemic inflammation and organ failure in patients with ACLF.
    J Hepatol. 2021;74:1117-1131.
    >> Share

    April 2021
  286. IZZY M, Lin G, Watt KD
    Non-selective beta blockers and mortality in decompensated Cirrhosis: Is Cirrhotic Cardiomyopathy the missing link?
    J Hepatol. 2021 Apr 28. pii: S0168-8278(21)00260.
    >> Share

  287. SENZOLO M, Garcia-Tsao G, Garcia-Pagan JC
    Current knowledge and management of portal vein thrombosis in cirrhosis.
    J Hepatol. 2021 Apr 27. pii: S0168-8278(21)00265.
    >> Share

  288. BETTINGER D, Kloeckner R, Boettler T, Thimme R, et al
    Reply: Freiburg index of post-TIPS survival (FIPS) a valid prognostic score in patients with cirrhosis but also an advisor against TIPS?
    J Hepatol. 2021 Apr 26. pii: S0168-8278(21)00264.
    >> Share

  289. VILLANUEVA C, Albillos A, Genesca J, Garcia-Pagan JC, et al
    Bacterial infections adversely influence the risk of decompensation and survival in compensated cirrhosis.
    J Hepatol. 2021 Apr 24. pii: S0168-8278(21)00257.
    >> Share

  290. TAPPER EB, Nikirk S, Parikh N, Zhao L, et al
    Falls are common, morbid, and predictable in patients with cirrhosis.
    J Hepatol. 2021 Apr 19. pii: S0168-8278(21)00247.
    >> Share

  291. TANAKA A, Hirohara J, Nakano T, Matsumoto K, et al
    Association of bezafibrate with transplant-free survival in patients with primary biliary cholangitis.
    J Hepatol. 2021 Apr 18. pii: S0168-8278(21)00245.
    >> Share

  292. SUNDARAM V
    Characterizing bacterial infections in acute-on-chronic liver failure among patients with cirrhosis from nonalcoholic steatohepatitis.
    J Hepatol. 2021 Apr 13. pii: S0168-8278(21)00240.
    >> Share

  293. AMPUERO J, Gallego-Duran R, Romero-Gomez M
    Reply to: "The predictive value of significant fibrosis for metabolic disturbances in patients with NAFLD".
    J Hepatol. 2021;74:971-972.
    >> Share

  294. LIU M, Sun L, Mao Y
    The predictive value of significant fibrosis for metabolic disturbances in patients with NAFLD.
    J Hepatol. 2021;74:970-971.
    >> Share

  295. DIETZ J, Di Maio VC, de Salazar A, Merino D, et al
    Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy.
    J Hepatol. 2021;74:801-810.
    >> Share

    March 2021
  296. MONTAGNESE S, Lauridsen M, Vilstrup H, Zarantonello L, et al
    A pilot study of Golexanolone, a new GABA-A receptor modulating steroid antagonist, in patients with covert hepatic encephalopathy.
    J Hepatol. 2021 Mar 24. pii: S0168-8278(21)00184.
    >> Share

  297. BASHO K, Bettinger D, Boettler T
    Reply to "IgG, a novel predictor for acute-on-chronic liver failure and survival in patients with decompensated cirrhosis?"
    J Hepatol. 2021 Mar 23. pii: S0168-8278(21)00187.
    >> Share

  298. POSE E, Torrents A, Reverter E, Perez-Campuzano V, et al
    A notable proportion of liver transplant candidates with alcohol-related cirrhosis can be delisted because of clinical improvement.
    J Hepatol. 2021 Mar 18. pii: S0168-8278(21)00175.
    >> Share

  299. LI J, Zhu X, Zhang M, Zhang Y, et al
    Limb expression 1-like (LIX1L) protein promotes cholestatic liver injury by regulating bile acid metabolism.
    J Hepatol. 2021 Mar 18. pii: S0168-8278(21)00177.
    >> Share

  300. PUTERA M, Teh KB, Kumar R, Wong YJ, et al
    Small esophageal varices in compensated cirrhosis patients: to treat or not to treat?
    J Hepatol. 2021 Mar 11. pii: S0168-8278(21)00167.
    >> Share

  301. STOCKHOFF L, Schneider H, Tergast TL, Cornberg M, et al
    Freiburg index of post-TIPS survival (FIPS) a valid prognostic score in patients with cirrhosis but also an advisor against TIPS?
    J Hepatol. 2021 Mar 11. pii: S0168-8278(21)00168.
    >> Share

  302. JAMIALAHMADI O, Bianco C, Pelusi S, Romeo S, et al
    Population attributable risk of cirrhosis and hepatocellular carcinoma due to genetic predisposition to fatty liver disease.
    J Hepatol. 2021 Mar 4. pii: S0168-8278(21)00164.
    >> Share

  303. MARJOT T, Moon AM, Cook JA, Abd-Elsalam S, et al
    Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: An international registry study.
    J Hepatol. 2021;74:567-577.
    >> Share

  304. JOYE R, Lador F, Aggoun Y, Farhat N, et al
    Outcome of paediatric portopulmonary hypertension in the modern management era: A case report of 6 patients.
    J Hepatol. 2021;74:742-747.
    >> Share

    February 2021
  305. SHAHINI E, Ahmed F
    Chronic fatigue should not be overlooked in primary biliary cholangitis.
    J Hepatol. 2021 Feb 25. pii: S0168-8278(21)00154.
    >> Share

  306. CON D, Clayton-Chubb D, Lubel J, Sawhney R, et al
    Dynamics of liver stiffness in chronic hepatitis B patients with concurrent metabolic-associated fatty liver disease.
    J Hepatol. 2021 Feb 19. pii: S0168-8278(21)00113.
    >> Share

  307. BARTOLI A, Gitto S, Sighinolfi P, Cursaro C, et al
    PRIMARY BILIARY CHOLANGITIS ASSOCIATED WITH SARS-COV2 INFECTION.
    J Hepatol. 2021 Feb 18. pii: S0168-8278(21)00106.
    >> Share

  308. TERGAST TL, Schultalbers M, Wedemeyer H, Cornberg M, et al
    IgG, a novel predictor for acute-on-chronic liver failure and survival in patients with decompensated cirrhosis?
    J Hepatol. 2021 Feb 3. pii: S0168-8278(21)00089.
    >> Share

  309. RIPOLL C, Zipprich A
    Open or closed window: That is the question.
    J Hepatol. 2021;74:485-486.
    >> Share

  310. ANAND A, Kumar R, Shalimar
    PREDICTing acute-on-chronic liver failure in patients with acute decompensation.
    J Hepatol. 2021;74:478-479.
    >> Share

  311. WINKLER M, Staniczek T, Kurschner SW, Schmid CD, et al
    Endothelial GATA4 controls liver fibrosis and regeneration by preventing a pathogenic switch in angiocrine signaling.
    J Hepatol. 2021;74:380-393.
    >> Share

    January 2021
  312. SCHATTENBERG JM, Pares A, Kowdley KV, Heneghan MA, et al
    A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA.
    J Hepatol. 2021 Jan 20. pii: S0168-8278(21)00022.
    >> Share

  313. SAMUEL D
    Systemic inflammation and liver cirrhosis complications: driving or secondary event? How to square the circle?
    J Hepatol. 2021 Jan 18. pii: S0168-8278(21)00001.
    >> Share

  314. RACHWAN RJ, Kutkut I, Timsina LR, Bou Chaaya RG, et al
    CAD-LT score effectively predicts risk of significant coronary artery disease in liver transplant candidates.
    J Hepatol. 2021 Jan 18. pii: S0168-8278(21)00016.
    >> Share

  315. JEPSEN P, West J
    We need stronger evidence for (or against) hepatocellular carcinoma surveillance.
    J Hepatol. 2021 Jan 16. pii: S0168-8278(21)00020.
    >> Share

  316. RAHIM MN, Theocharidou E, Yen Lau KG, Ahmed R, et al
    Safety and efficacy of in vitro fertilisation in patients with chronic liver disease and liver transplantation recipients.
    J Hepatol. 2021 Jan 15. pii: S0168-8278(21)00005.
    >> Share

  317. FAN R, Yin X, Hou J
    Reply to "External validation of aMAP risk score in Chronic hepatitis C genotype 4 patients with liver cirrhosis who achieved SVR following DAAs".
    J Hepatol. 2021 Jan 13. pii: S0168-8278(21)00011.
    >> Share

  318. BURTON AR, Pallett LJ
    IL-2 leaves its mark in cirrhosis.
    J Hepatol. 2021 Jan 6. pii: S0168-8278(20)33833.
    >> Share

  319. BOSCH J
    Small diameter shunts should lead to safe expansion of the use of TIPS.
    J Hepatol. 2021;74:230-234.
    >> Share

  320. TEO K, Abeysekera KWM, Adams L, Aigner E, et al
    rs641738C>T near MBOAT7 is associated with liver fat, ALT and fibrosis in NAFLD: A meta-analysis.
    J Hepatol. 2021;74:20-30.
    >> Share

    December 2020
  321. FERRUSQUIA-ACOSTA J, Turco L, Hernandez-Gea V
    Reply to: "Underestimation of portal pressures by wedge hepatic venous pressures in patients with non-alcoholic steatohepatitis related cirrhosis- Possibilities and implications".
    J Hepatol. 2020 Dec 29. pii: S0168-8278(20)33837.
    >> Share

  322. SHARMA S, Anand A, Saraya A
    Underestimation of portal pressures by wedge hepatic venous pressures in patients with non-alcoholic steatohepatitis related cirrhosis- Possibilities and implications.
    J Hepatol. 2020 Dec 22. pii: S0168-8278(20)33736.
    >> Share

  323. WANG H, Chen J
    Reply to: "Prospective validation of Baveno VI criteria in virally supressed HBV cirrhosis - more evidence is needed".
    J Hepatol. 2020 Dec 19. pii: S0168-8278(20)33839.
    >> Share

  324. SHARMA S, Agarwal S
    Prospective validation of Baveno VI criteria in virally supressed HBV cirrhosis - more evidence is needed.
    J Hepatol. 2020 Dec 19. pii: S0168-8278(20)33687.
    >> Share

  325. LISMAN T, Luyendyk JP
    Response to "The Systemic Inflammation Hypothesis: Towards a New Paradigm of Acute Decompensation and Multiorgan Failure in Cirrhosis".
    J Hepatol. 2020 Dec 18. pii: S0168-8278(20)33890.
    >> Share

  326. NINGARHARI M, Caruso S, Hirsch TZ, Bayard Q, et al
    Telomere length is key to hepatocellular carcinoma diversity and telomerase addiction is an actionable therapeutic target.
    J Hepatol. 2020 Dec 15. pii: S0168-8278(20)33846.
    >> Share

  327. AVANCENA ALV, Miller N, Uttal SE, Hutton DW, et al
    Cost-effectiveness of alcohol use treatments in patients with alcohol-related cirrhosis.
    J Hepatol. 2020 Dec 13. pii: S0168-8278(20)33841.
    >> Share

  328. MARINO Z, Darnell A, Lens S, Sapena V, et al
    Corrigendum to "Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules" [J Hepatol (2019) 874-884].
    J Hepatol. 2020 Dec 11. pii: S0168-8278(20)33773.
    >> Share

  329. ARROYO V, Angeli P, Moreau R, Jalan R, et al
    The Systemic Inflammation Hypothesis: Towards a New Paradigm of Acute Decompensation and Multiorgan Failure in Cirrhosis.
    J Hepatol. 2020 Dec 7. pii: S0168-8278(20)33836.
    >> Share

  330. TREBICKA J, Fernandez J, Arroyo V
    Reply to: Correspondence on 'The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology'.
    J Hepatol. 2020 Dec 2. pii: S0168-8278(20)33765.
    >> Share

  331. WEIL D, Thevenot T, Saas P, Di Martino V, et al
    Relevance of platelet-derived microvesicles in cirrhosis: The debate remains open.
    J Hepatol. 2020 Dec 2. pii: S0168-8278(20)33745.
    >> Share

  332. BOYER-DIAZ Z, Aristu-Zabalza P, Andres-Rozas M, Robert C, et al
    Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease.
    J Hepatol. 2020 Dec 2. pii: S0168-8278(20)33832.
    >> Share

  333. TANWAR S, Srivastava A, Rosenberg W
    Errors in modeling misrepresent the utility of the enhanced liver fibrosis test in the management of non-alcoholic fatty liver disease.
    J Hepatol. 2020;73:1580-1581.
    >> Share

  334. HERNAEZ R, Liu Y, Kanwal F
    Reply to: "Model for end-stage liver disease-sodium in acute-on-chronic liver failure".
    J Hepatol. 2020;73:1579-1580.
    >> Share

  335. VALI Y, Anstee QM, Bossuyt PM
    Reply to: "Errors in modeling misrepresent the utility of the enhanced liver fibrosis test in the management of non-alcoholic fatty liver disease".
    J Hepatol. 2020;73:1582-1583.
    >> Share

  336. RATZIU V, Rinella M, Beuers U, Loomba R, et al
    The times they are a-changin' (for NAFLD as well).
    J Hepatol. 2020;73:1307-1309.
    >> Share

    November 2020
  337. BIANCO C, Jamialahmadi O, Pelusi S, Baselli G, et al
    Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores.
    J Hepatol. 2020 Nov 25. pii: S0168-8278(20)33811.
    >> Share

  338. KELLUM JA, Nadim MK
    Acute kidney disease and cirrhosis.
    J Hepatol. 2020 Nov 23. pii: S0168-8278(20)33756.
    >> Share

  339. KRASSENBURG LAP, Maan R, Ramji A, Manns MP, et al
    Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity.
    J Hepatol. 2020 Nov 23. pii: S0168-8278(20)33805.
    >> Share

  340. TREBICKA J, Fernandez J, Papp M, Caraceni P, et al
    PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis.
    J Hepatol. 2020 Nov 20. pii: S0168-8278(20)33772.
    >> Share

  341. CHEN H, Cai J, Wang J, Qiu Y, et al
    Targeting Nestin(+) hepatic stellate cells ameliorates liver fibrosis by facilitating TbetaRI degradation.
    J Hepatol. 2020 Nov 17. pii: S0168-8278(20)33769.
    >> Share

  342. MEHTANI R, Roy A, Verma N, Premkumar M, et al
    Beta-blockers in refractory ascites - is it truly the end of the road?
    J Hepatol. 2020;73:1290-1291.
    >> Share

  343. TELLEZ L, Ibanez-Samaniego L, Banares R, Albillos A, et al
    Reply to: "Beta-blockers in refractory ascites - is it truly the end of the road?"
    J Hepatol. 2020;73:1291-1292.
    >> Share

    October 2020
  344. MOHS A, Otto T, Schneider KM, Peltzer M, et al
    Hepatocyte-specific NRF2 activation controls fibrogenesis and carcinogenesis in steatohepatitis.
    J Hepatol. 2020 Oct 24. pii: S0168-8278(20)33695.
    >> Share

  345. BASHO K, Zoldan K, Schultheiss M, Bettinger D, et al
    IL-2 contributes to cirrhosis-associated immune dysfunction by impairing follicular T helper cells in advanced cirrhosis.
    J Hepatol. 2020 Oct 23. pii: S0168-8278(20)33692.
    >> Share

  346. SHIHA G, Mikhail N, Soliman R
    External validation of aMAP risk score in Chronic hepatitis C genotype 4 patients with liver cirrhosis who achieved SVR following DAAs.
    J Hepatol. 2020 Oct 23. pii: S0168-8278(20)33688.
    >> Share

  347. DEPAIRE M, Larrue H, Rudler M, Nault JC, et al
    Futility criteria for preemptive TIPS in patients with cirrhosis and variceal bleeding are still missing in most severe patients!
    J Hepatol. 2020 Oct 23. pii: S0168-8278(20)33689.
    >> Share

  348. MOGA L, Laroyenne A, Larrue H, Bureau C, et al
    Patients with NAFLD do not have severe portal hypertension in the absence of cirrhosis.
    J Hepatol. 2020 Oct 23. pii: S0168-8278(20)33691.
    >> Share

  349. FERRUSQUIA-ACOSTA J, Bassegoda O, Turco L, Reverter E, et al
    Agreement between wedged hepatic venous pressure and portal pressure in non-alcoholic steatohepatitis-related cirrhosis.
    J Hepatol. 2020 Oct 14. pii: S0168-8278(20)33683.
    >> Share

  350. CARBONE M, Ronca V, Invernizzi P
    Reply to: "A spotlight on natural killer cells in primary biliary cholangitis".
    J Hepatol. 2020 Oct 14. pii: S0168-8278(20)33663.
    >> Share

  351. HYDES T, Khakoo SI
    A spotlight on natural killer cells in primary biliary cholangitis.
    J Hepatol. 2020 Oct 14. pii: S0168-8278(20)33595.
    >> Share

  352. WANG H, Wen B, Chang X, Wu Q, et al
    Baveno VI criteria and spleen stiffness measurement rule out high-risk varices in virally suppressed HBV-related cirrhosis.
    J Hepatol. 2020 Oct 8. pii: S0168-8278(20)33678.
    >> Share

  353. CAI SY, Yu D, Soroka CJ, Wang J, et al
    Hepatic NFAT signaling regulates the expression of inflammatory cytokines in cholestasis.
    J Hepatol. 2020 Oct 8. pii: S0168-8278(20)33680.
    >> Share

  354. FRENETTE C, Kayali Z, Mena E, Mantry PS, et al
    Emricasan to prevent new decompensation in patients with NASH-related decompensated cirrhosis.
    J Hepatol. 2020 Oct 7. pii: S0168-8278(20)33673.
    >> Share

  355. ZHU C, Ho YJ, Salomao MA, Dapito DH, et al
    Notch activity characterizes a common hepatocellular carcinoma subtype with unique molecular and clinicopathologic features.
    J Hepatol. 2020 Oct 7. pii: S0168-8278(20)33676.
    >> Share

  356. MAGAZ M, Alvarez-Larran A, Colomer D, Lopez M, et al
    Reply to: Correspondence on "Next-generation sequencing in the diagnosis of non-cirrhotic splanchnic vein thrombosis".
    J Hepatol. 2020 Oct 2. pii: S0168-8278(20)33621.
    >> Share

  357. O'BRIEN A, Karvellas CJ
    Acute-on-chronic liver failure: The challenge of PREDICTing who and when.
    J Hepatol. 2020;73:755-756.
    >> Share

    September 2020
  358. GRONBAEK H, Gantzel RH, Laursen TL, Kazankov K, et al
    Macrophage markers and innate immunity in cirrhosis.
    J Hepatol. 2020 Sep 26. pii: S0168-8278(20)30486.
    >> Share

  359. TREMBLAY D, Mascarenhas J, Schiano T, Naymagon L, et al
    Comment on "Next-generation sequencing in the diagnosis of non-cirrhotic splanchnic vein thrombosis".
    J Hepatol. 2020 Sep 24. pii: S0168-8278(20)30531.
    >> Share

  360. ZHENG KI, Liu C, Li J, Zhao L, et al
    Validation of Baveno VI and expanded Baveno VI criteria to identify high-risk varices in patients with MAFLD-related compensated cirrhosis.
    J Hepatol. 2020 Sep 21. pii: S0168-8278(20)30447.
    >> Share

  361. HIRSCHFIELD GM, Beuers U, Kupcinskas L, Ott P, et al
    A placebo-controlled randomised trial of budesonide for primary biliary cholangitis following an insufficient response to UDCA.
    J Hepatol. 2020 Sep 17. pii: S0168-8278(20)33623.
    >> Share

  362. DYSON JK, Jones DEJ
    UDCA prophylaxis for post-transplant PBC recurrence prevention: Time to change practice.
    J Hepatol. 2020;73:499-501.
    >> Share

  363. ILIC I, Milovanovic T
    The risk-benefit assessment of liver biopsy in times of non-invasive screening for liver fibrosis.
    J Hepatol. 2020;73:701-702.
    >> Share

    August 2020
  364. CHARETTE JH, Burak KW, Coffin CS, Congly SE, et al
    Evaluating the role of transient elastography post chronic hepatitis C treatment to predict hepatocellular carcinoma.
    J Hepatol. 2020 Aug 31. pii: S0168-8278(20)30458.
    >> Share

  365. GENESCA J
    Reply to: "Evaluating the role of transient elastography post chronic hepatitis C treatment to predict hepatocellular carcinoma".
    J Hepatol. 2020 Aug 24. pii: S0168-8278(20)30484.
    >> Share


  366. EASL recommendations on treatment of hepatitis C - Final update of the series.
    J Hepatol. 2020 Aug 21. pii: S0168-8278(20)30548.
    >> Share

  367. CHALOUNI M, Pol S, Sogni P, Fontaine H, et al
    Increased mortality in HIV/HCV-coinfected compared to HCV-monoinfected patients in the DAA era due to non-liver-related death.
    J Hepatol. 2020 Aug 13. pii: S0168-8278(20)30535.
    >> Share

  368. CALVARUSO V, Craxi A
    Hepatic benefits of HCV cure.
    J Hepatol. 2020 Aug 7. pii: S0168-8278(20)30530.
    >> Share

  369. CALVARUSO V, Bruix J
    Towards personalized screening for hepatocellular carcinoma: still not there.
    J Hepatol. 2020 Aug 5. pii: S0168-8278(20)30405.
    >> Share

  370. GAUL S, Leszczynska A, Alegre F, Kaufmann B, et al
    Hepatocyte pyroptosis and release of inflammasome particles induce stellate cell activation and liver fibrosis.
    J Hepatol. 2020 Aug 4. pii: S0168-8278(20)30522.
    >> Share

  371. PRAKTIKNJO M, Torner J, Simon-Talero M, Gu W, et al
    Reply to: "Definition of SPSS: we need to speak the same language": Computer-assisted image processing for better quantification.
    J Hepatol. 2020;73:464-465.
    >> Share

  372. NICOARA-FARCAU O, Wang X, Luo X
    Definition of SPSS: we need to speak the same language.
    J Hepatol. 2020;73:463-464.
    >> Share

    July 2020
  373. DU M, Wang X, Yuan L, Liu B, et al
    Targeting NFATc4 attenuates non-alcoholic steatohepatitis in mice.
    J Hepatol. 2020 Jul 24. pii: S0168-8278(20)30482.
    >> Share

  374. KJAERGAARD K, Frisch K, Sorensen M, Munk OL, et al
    Obeticholic acid improves hepatic bile acid excretion in patients with primary biliary cholangitis.
    J Hepatol. 2020 Jul 24. pii: S0168-8278(20)30481.
    >> Share

  375. SABOO K, Shamsaddini A, Iyer MV, Hu C, et al
    Sex is associated with differences in gut microbial composition and function in hepatic encephalopathy.
    J Hepatol. 2020 Jul 14. pii: S0168-8278(20)30457.
    >> Share

  376. DEEB M, Karlsen TH, Hirschfield GM
    The 6 C's of Primary Sclerosing Cholangitis.
    J Hepatol. 2020 Jul 7. pii: S0168-8278(20)30436.
    >> Share

  377. ROULOT D, Brichler S, Layese R, BenAbdesselam Z, et al
    Origin, HDV genotype and persistent viremia determine outcome and treatment response in patients with chronic hepatitis Delta.
    J Hepatol. 2020 Jul 4. pii: S0168-8278(20)30441.
    >> Share

  378. RINELLA ME, Noureddin M
    STELLAR 3 and STELLAR 4: Lessons from the fall of Icarus.
    J Hepatol. 2020;73:9-11.
    >> Share

  379. SHAH S, Dhami-Shah H, Kamble S, Shukla A, et al
    FIB-4 cut-off of 1.3 may be inappropriate in a primary care referral pathway for patients with non-alcoholic fatty liver disease.
    J Hepatol. 2020;73:216-217.
    >> Share

  380. TSOCHATZIS EA, Srivastava A, Rosenberg W
    Reply to: "FIB-4 cut off of 1.3 may be inappropriate in a primary care referral pathway for patients with non-alcoholic fatty liver disease".
    J Hepatol. 2020;73:217-218.
    >> Share

    June 2020
  381. PAPATHEODORIDIS GV, Dalekos GN, Idilman R, Sypsa V, et al
    Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B.
    J Hepatol. 2020 Jun 15. pii: S0168-8278(20)30382.
    >> Share

  382. LENS S, Baiges A, Alvarado E, LLop E, et al
    Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension.
    J Hepatol. 2020 Jun 11. pii: S0168-8278(20)30368.
    >> Share

  383. MAK LY, Wan-Hin Hui R, Fung J, Liu F, et al
    Diverse effects of hepatic steatosis on fibrosis progression and functional cure in virologically quiescent chronic hepatitis B.
    J Hepatol. 2020 Jun 3. pii: S0168-8278(20)30361.
    >> Share

  384. HARMS MH, van Buuren HR, van der Meer AJ
    Reply to: "Switching vs. add-on strategy in PBC treatment: Lessons from UDCA and bezafibrate experience".
    J Hepatol. 2020;72:1211-1212.
    >> Share

  385. CORPECHOT C, Rousseau A, Chazouilleres O
    Switching vs. add-on strategy in PBC treatment: Lessons from UDCA and bezafibrate experience.
    J Hepatol. 2020;72:1210-1211.
    >> Share

  386. KHORUTS A, Bajaj JS
    Reply to: " 'You know my name, but not my story' - Deciding on an accurate nomenclature for faecal microbiota transplantation": Intestinal microbiota transplantation: Naming a new paradigm.
    J Hepatol. 2020;72:1213-1214.
    >> Share

  387. PHILIPS CA, Ahamed R, Rajesh S, Augustine P, et al
    'You know my name, but not my story' - Deciding on an accurate nomenclature for faecal microbiota transplantation.
    J Hepatol. 2020;72:1212-1213.
    >> Share

    May 2020
  388. RIOU J, Canivet CM, Boursier J
    Reply to: "Accurate diagnosis of NAFLD-related hepatic fibrosis with non-invasive methods: A comment for moving forward".
    J Hepatol. 2020 May 15. pii: S0168-8278(20)30233.
    >> Share

  389. LI W
    Accurate diagnosis of NAFLD-related hepatic fibrosis with non-invasive methods: A comment for moving forward.
    J Hepatol. 2020 May 13. pii: S0168-8278(20)30179.
    >> Share

  390. WANG S, Friedman SL
    Hepatic fibrosis: A convergent response to liver injury that is reversible.
    J Hepatol. 2020 May 8. pii: S0168-8278(20)30170.
    >> Share

  391. GAO J, Wei B, de Assuncao TM, Liu Z, et al
    Hepatic stellate cell autophagy inhibits extracellular vesicle release to attenuate liver fibrosis.
    J Hepatol. 2020 May 7. pii: S0168-8278(20)30290.
    >> Share

  392. STATTERMAYER AF, Halilbasic E, Wrba F, Ferenci P, et al
    Variants in ABCB4 (MDR3) across the spectrum of cholestatic liver diseases in adults.
    J Hepatol. 2020 May 3. pii: S0168-8278(20)30280.
    >> Share

  393. BATES J, Vijayakumar A, Ghoshal S, Marchand B, et al
    Acetyl-CoA carboxylase inhibition disrupts metabolic reprogramming during hepatic stellate cell activation.
    J Hepatol. 2020 May 3. pii: S0168-8278(20)30281.
    >> Share

  394. SAPENA V, Rios J, Torres F, Marino Z, et al
    Reply to: "The reported 'clear cut time association between interferon-free treatment and HCC' is anything but clear cut".
    J Hepatol. 2020;72:1036-1037.
    >> Share

  395. INNES HA, McDonald SA, Barclay ST, Irving WL, et al
    The reported 'clear cut time association between interferon-free treatment and HCC' is anything but clear cut.
    J Hepatol. 2020;72:1034-1035.
    >> Share

    April 2020
  396. LEFERE S, Puengel T, Hundertmark J, Penners C, et al
    Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages.
    J Hepatol. 2020 Apr 29. pii: S0168-8278(20)30269.
    >> Share

  397. STOCKDALE AJ, Kreuels B, Henrion MYR, Giorgi E, et al
    The global prevalence of hepatitis D virus infection: systematic review and meta-analysis.
    J Hepatol. 2020 Apr 23. pii: S0168-8278(20)30220.
    >> Share

  398. CORPECHOT C, Chazouilleres O, Belnou P, Montano-Loza AJ, et al
    Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis.
    J Hepatol. 2020 Apr 7. pii: S0168-8278(20)30205.
    >> Share

  399. PARISINOS CA, Wilman HR, Thomas EL, Kelly M, et al
    Genome-wide and Mendelian randomisation studies of liver MRI yield insights into the pathogenesis of steatohepatitis.
    J Hepatol. 2020 Apr 2. pii: S0168-8278(20)30194.
    >> Share

    March 2020
  400. KOWDLEY KV, Vuppalanchi R, Levy C, Floreani A, et al
    A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis.
    J Hepatol. 2020 Mar 9. pii: S0168-8278(20)30160.
    >> Share

  401. SAVALE L, Guimas M, Ebstein N, Fertin M, et al
    Portopulmonary hypertension in the current era of pulmonary hypertension management.
    J Hepatol. 2020 Mar 4. pii: S0168-8278(20)30119.
    >> Share

    February 2020
  402. BERARDI G, Troisi RI
    Reply to: "Nomogram to predict surgical hepatocellular carcinoma with Child-Pugh B: Feasibility and overlooked predictors".
    J Hepatol. 2020 Feb 28. pii: S0168-8278(20)30069.
    >> Share

  403. HUO TI, Liu PH, Hsu CY
    Nomogram to predict surgical hepatocellular carcinoma with Child-Pugh B: Feasibility and overlooked predictors.
    J Hepatol. 2020 Feb 28. pii: S0168-8278(20)30015.
    >> Share

  404. REBOUISSOU S, Nault JC
    Advances in molecular classification and precision oncology in hepatocellular carcinoma.
    J Hepatol. 2020;72:215-229.
    >> Share

    December 2019
  405. PAISANT A, Vilgrain V, Riou J, Oberti F, et al
    Comparison of extracellular and hepatobiliary MR contrast agents for the diagnosis of small HCCs.
    J Hepatol. 2019 Dec 20. pii: S0168-8278(19)30725.
    >> Share

  406. SOLE C, Sola E, Kamath PS, Gines P, et al
    Lack of evidence for a continuum between hepatorenal syndrome and acute tubular necrosis.
    J Hepatol. 2019 Dec 10. pii: S0168-8278(19)30554.
    >> Share

  407. SHE S, Wu X, Zheng D, Pei X, et al
    PSMP/MSMP promotes hepatic fibrosis through CCR2 and represents a novel therapeutic target.
    J Hepatol. 2019 Dec 5. pii: S0168-8278(19)30654.
    >> Share

  408. GARCIA-TSAO G, Angeli P, Nadim MK, Parikh CR, et al
    Reply to: "Lack of evidence for a continuum between hepatorenal syndrome and acute tubular necrosis".
    J Hepatol. 2019 Dec 3. pii: S0168-8278(19)30673.
    >> Share

    November 2019
  409. HE X, Wang Y, Fan X, Lei N, et al
    A schistosome miRNA promotes host hepatic fibrosis by targeting transforming growth factor beta receptor III.
    J Hepatol. 2019 Nov 15. pii: S0168-8278(19)30674.
    >> Share

  410. HAMMOUTENE A, Biquard L, Lasselin J, Kheloufi M, et al
    A defect in endothelial autophagy occurs in patients with nonalcoholic steatohepatitis and promotes inflammation and fibrosis.
    J Hepatol. 2019 Nov 11. pii: S0168-8278(19)30669.
    >> Share

    October 2019
  411. SUNDARAM V, Kogachi S, Wong RJ, Karvellas CJ, et al
    Effect of the clinical course of acute on chronic liver failure prior to liver transplantation on post-transplant survival.
    J Hepatol. 2019 Oct 25. pii: S0168-8278(19)30640.
    >> Share

  412. BRIL F, Barb D, Lomonaco R, Lai J, et al
    Change in hepatic fat content measured by MRI does not predict treatment-induced histological improvement of steatohepatitis.
    J Hepatol. 2019 Oct 4. pii: S0168-8278(19)30584.
    >> Share

    September 2019
  413. CLEMENTS O, Eliahoo J, Un Kim J, Taylor-Robinson SD, et al
    Risk Factors for Intrahepatic and Extrahepatic Cholangiocarcinoma: a systematic review and meta-analysis.
    J Hepatol. 2019 Sep 16. pii: S0168-8278(19)30543.
    >> Share

    August 2019
  414. BHANGUI P, Lim C, Levesque E, Salloum C, et al
    Novel Classification of Nonmalignant Portal Vein Thrombosis: A guide to Surgical Decision Making during Liver Transplantation.
    J Hepatol. 2019 Aug 20. pii: S0168-8278(19)30479.
    >> Share

  415. DEGASPERI E, Spinetti A, Lombardi A, Landonio S, et al
    Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous daa failure.
    J Hepatol. 2019 Aug 6. pii: S0168-8278(19)30461.
    >> Share

    July 2019
  416. DHIMAN RK, Grover GS, Premkumar M, Taneja S, et al
    Decentralized Care with Generic Direct-Acting Antivirals in the Management of Chronic Hepatitis C in a Public Health Care Setting.
    J Hepatol. 2019 Jul 17. pii: S0168-8278(19)30414.
    >> Share

  417. GORG B, Karababa A, Schutz E, Paluschinski M, et al
    O-GlcNAcylation-dependent upregulation of HO1 triggers ammonia-induced oxidative stress and senescence in hepatic encephalopathy.
    J Hepatol. 2019 Jul 4. pii: S0168-8278(19)30392.
    >> Share

    June 2019
  418. LLANERAS J, Riveiro-Barciela M, Lens S, Diago M, et al
    Effectiveness and Safety of Sofosbuvir/Velpatasvir/ Voxilaprevir in Patients with Chronic Hepatitis C Previously Treated with DAAs.
    J Hepatol. 2019 Jun 13. pii: S0168-8278(19)30345.
    >> Share

  419. BORGIA SM, Dearden J, Yoshida EM, Shafran SD, et al
    Sofosbuvir/Velpatasvir for 12 Weeks in Hepatitis C Virus-Infected Patients with End-Stage Renal Disease Undergoing Dialysis.
    J Hepatol. 2019 Jun 10. pii: S0168-8278(19)30343.
    >> Share

  420. RAVICHANDRAN G, Neumann K, Berkhout LK, Weidemann S, et al
    Interferon-gamma-dependent immune responses contribute to the pathogenesis of sclerosing cholangitis in mice.
    J Hepatol. 2019 Jun 4. pii: S0168-8278(19)30309.
    >> Share

    May 2019
  421. DE TYMOWSKI C, Depret F, Soussi S, Nabila M, et al
    Contributing factors and outcomes of burn-associated cholestasis.
    J Hepatol. 2019 May 29. pii: S0168-8278(19)30292.
    >> Share

  422. ALAVI M, Law MG, Valerio H, Grebely J, et al
    Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia.
    J Hepatol. 2019 May 9. pii: S0168-8278(19)30275.
    >> Share

  423. NISHIO T, Hu R, Koyama Y, Liang S, et al
    Activated Hepatic Stellate Cells and Portal Fibroblasts contribute to cholestatic liver fibrosis in MDR2 knockout mice.
    J Hepatol. 2019 May 6. pii: S0168-8278(19)30273.
    >> Share

    April 2019
  424. HARMS MH, van Buuren HR, Corpechot C, Thorburn D, et al
    Ursodeoxycholic Acid Therapy and Liver Transplant-free Survival in Patients with Primary Biliary Cholangitis.
    J Hepatol. 2019 Apr 10. pii: S0168-8278(19)30228.
    >> Share

    March 2019
  425. ARONSON SJ, Bakker RS, Shi X, Duijst S, et al
    Liver-directed gene therapy results in long term correction of progressive familial intrahepatic cholestasis type 3 in mice.
    J Hepatol. 2019 Mar 29. pii: S0168-8278(19)30192.
    >> Share

  426. WIJAYA RS, Read SA, Schibeci S, Eslam M, et al
    KLRG1+ natural killer cells exert a novel anti-fibrotic function in chronic hepatitis B.
    J Hepatol. 2019 Mar 21. pii: S0168-8278(19)30182.
    >> Share

  427. TSUNODA T, Kakinuma S, Miyoshi M, Kamiya A, et al
    Loss of Fibrocystin Promotes Interleukin-8-Dependent Proliferation and CTGF Production of Biliary Epithelium.
    J Hepatol. 2019 Mar 15. pii: S0168-8278(19)30146.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016